## 1 Tonic dopamine and biases in value learning linked through a

## 2 biologically inspired reinforcement learning model

3	
4	
5	Sandra Romero Pinto <sup>1,2</sup> , Naoshige Uchida <sup>1</sup>
6	
7	Affiliations:
8	<sup>1</sup> Department of Molecular and Cellular Biology, Center for Brain Science, Harvard University,
9	Cambridge, MA 02138, USA
10	<sup>2</sup> Program in Speech and Hearing Bioscience and Technology, Division of Medical Sciences,
11	Harvard Medical School, Boston, MA 02115, USA
12	
13	Correspondence: <u>uchida@mcb.harvard.edu</u> (N.U); <u>sromeropinto@g.harvard.edu</u> (S.R.P)
14	
15	
16	

#### 17 Abstract

18

A hallmark of various psychiatric disorders is biased future predictions. Here we examined the 19 20 mechanisms for biased value learning using reinforcement learning models incorporating recent 21 findings on synaptic plasticity and opponent circuit mechanisms in the basal ganglia. We show 22 that variations in tonic dopamine can alter the balance between learning from positive and 23 negative reward prediction errors, leading to biased value predictions. This bias arises from the 24 sigmoidal shapes of the dose-occupancy curves and distinct affinities of D1- and D2-type 25 dopamine receptors: changes in tonic dopamine differentially alters the slope of the dose-26 occupancy curves of these receptors, thus sensitivities, at baseline dopamine concentrations. We 27 show that this mechanism can explain biased value learning in both mice and humans and may 28 also contribute to symptoms observed in psychiatric disorders. Our model provides a foundation 29 for understanding the basal ganglia circuit and underscores the significance of tonic dopamine in 30 modulating learning processes. 31 32 33 Introduction 34

35 Our ability to predict the outcomes of our actions is crucial in selecting and motivating 36 appropriate actions. Systematic biases in future predictions or expectations, however, can lead to maladaptive behaviors, such as those observed in patients with various psychiatric disorders<sup>1-4</sup>. 37 38 For example, overly negative or pessimistic predictions can contribute to major depression<sup>1,5</sup>, 39 whereas excessively positive or optimistic predictions may be associated with pathological gambling, addiction, and mania $^{3,4,6-8}$ . Despite the importance of understanding the causes of 40 41 biased future predictions, the biological mechanisms underlying them remain poorly understood. 42 43 Our future expectations and decisions are shaped by experiences of positive and negative events.

44 The process of learning from outcomes has been modeled using reinforcement learning (RL)

45 models $^{9-12}$ , where value predictions are updated based on reward prediction errors (RPEs), that is

46 the discrepancy between received and expected outcomes. In addition to its role in learning,

 $\mathbf{2}$ 

47 recent studies have indicated the importance of RPEs in mood; these studies have suggested that
48 mood depends not on the absolute goodness of outcomes, but rather on the recent history of
49 RPEs<sup>13,14</sup>.

50

51 In the brain, dopamine is thought to be a key regulator in this process of learning from positive 52 and negative outcomes. The dynamics of dopamine are often categorized into two modes: tonic 53 and phasic. Tonic dopamine refers to "baseline" dopamine that operates on a long timescale such 54 as tens of seconds or minutes, while phasic activity refers to transient changes that occur at a much shorter, sub-second timescale, often triggered by external stimuli<sup>15–18</sup>. A significant body 55 56 of evidence has shown that phasic responses of dopamine neurons convey RPEs and drive learning of values and actions<sup>17–20</sup>. On the other hand, changes in tonic dopamine might also 57 58 modulate value learning, yet whether and how the level of tonic dopamine modulates learning 59 remain poorly understood.

60

61 Previous studies have reported that patients with psychiatric disorders exhibit biased learning 62 from positive versus negative outcomes. For one, some studies have shown that patients with 63 major depression have a reduced sensitivity in learning from rewarding events, while their ability to learn from negative events remains relatively intact<sup>1,5,21</sup>. Similarly, patients with Parkinson's 64 disease are better at learning from negative than positive outcomes<sup>22,23</sup>. Analysis of these patients 65 66 using RL models has suggested that biases in learning can be explained by alterations in specific 67 parameters in RL models, such as the learning rate parameters or the sensitivity to positive and 68 negative outcomes. For example, some studies have suggested that anhedonia in major 69 depressive disorder may correspond to a reduced learning rate from positive compared to 70 negative outcomes<sup>1</sup>.

71

Mechanistically, some of these changes in RL parameters can be linked to altered functions of
 dopamine. First, it has been shown that dopamine synthesis capacity, an approximate indicator of
 baseline dopamine levels, in the striatum, as measured using positron emission tomography

75 (PET), correlates with learning rate parameters<sup>24</sup>. Second, dopamine medications can change the balance between learning from positive and negative outcomes<sup>22,24,25</sup>. Third, responses to 76 positive outcomes in the nucleus accumbens (NAc), as measured based on blood oxygenation-77 78 dependent (BOLD) signals, are reduced in patients with psychiatric disorders such as 79 depression<sup>26–29</sup>. These observations point to important roles of reinforcement learning processes 80 and dopamine in regulating value learning. However, the parameters in RL models remain an 81 abstract entity, and biological processes underlying changes in these parameters are still largely 82 unknown.

83

One limitation in most RL models used in previous studies is that they do not reflect key neural circuit architectures in the brain (but see <sup>30–32</sup>) nor recent findings on intracellular signaling and plasticity rules that can constrain how dopamine functions in biological circuits<sup>33–35</sup>.

87 Incorporating these key biological factors may lead to better understanding of how changes in

88 RL parameters may arise in psychiatric disorders. Furthermore, recent studies have found that

the activity of dopamine neurons is consistent with a novel RL algorithm called distributional

90  $RL^{36-38}$ . Distributional RL takes into account the diversity in dopamine signals, and a population

91 of dopamine neurons together encodes the entire distribution of rewards, not just the average.

92 Although distributional RL has shown to be efficient in solving various RL problems in artificial

93 intelligence<sup>37,39</sup>, how distributional RL can be implemented in biological neural circuits and how

94 distributional RL relates to biased value learning remain to be examined.

95

96 In this study, we sought to identify potential mechanisms that cause biased value predictions 97 using biologically inspired RL models. To this goal, we first construct an RL model that 98 incorporates recent biological findings, such as intracellular signaling and synaptic plasticity 99 rules as well as the basic circuit architecture in the brain<sup>32</sup>. Based on this model, we propose two 100 potential biological mechanisms that can cause optimistic or pessimistic biases in value 101 predictions. We will then show that some existing data can be explained by one of these models.

102 Finally, we will show how our model can provide an account of how biases in value predictions

- 103 arise in psychiatric disorders.
- 104
- 105
- 106 **Results**
- 107

#### 108 **Basic reinforcement learning algorithms**

109 Here we first formulate basic RL algorithms that will become the basis of our later models. In

110 RL, an agent learns to predict the expectation of future rewards associated with a given state, a

111 quantity termed as  $value^{11}$ . For simplicity, we will drop the dependency on time here, but note

112 that the basic results hold even if time is considered (Methods 1.1). Learning of value is driven

113 by RPEs ( $\delta$ ), the discrepancy between the actual and expected reward (*r* and *V*, respectively)

114 (Eq1). To improve the accuracy of the value prediction, RPEs are utilized to update the estimate

115 of *V*. This is done iteratively by adding a fraction ( $\alpha$ ) of  $\delta$  (Eq2) where  $\alpha$  defines the learning 116 rate.

117

$$\delta = r - V \tag{1}$$

119 
$$V \leftarrow V + \alpha \cdot \delta$$
 (2)

120

121 When the magnitude of reward r is fixed (i.e., deterministic environment), the value V learned 122 through this algorithm (Eq 1 and 2) converges on r and the RPE converges on zero. When the 123 magnitude of reward r varies stochastically trial-to-trial, the value at convergence fluctuates 124 around the expected value of the reward distribution (see Methods 1) (Fig. 1a) and the RPE 125 around zero.

126

127 **Risk-sensitive RL.** In the framework called risk-sensitive RL<sup>40</sup>, learning rates are defined 128 separately for positive and negative RPEs (denoted by  $\alpha^+, \alpha^-$ ).

129

130  $V \leftarrow V + \alpha^+ \cdot \delta \quad \text{if } \delta > 0$  (3)

#### 131 $V \leftarrow V + \alpha^- \cdot \delta$ if $\delta < 0$

132

133 In the presence of stochastic rewards, when the learning rates between positive and negative 134 RPEs are different, the value learned through this algorithm (Eq 1 and 3) does not converge on 135 the expected value, but instead on a value higher or lower than the expected value depending on the relative amplitude of the learning rates  $\alpha^+, \alpha^-$ . This algorithm, therefore, develops optimistic 136 137 or pessimistic value expectations, respectively. This learning algorithm is called "risk-sensitive" 138 because values of probabilistic (risky) rewards are biased compared to deterministic (certain) 139 rewards, and, therefore, the agent develops a preference between risky and certain rewards even 140 when the expected values are the same (Fig. 1b).

141

142 **Distributional RL**. The concept of asymmetric updates has been utilized in a novel RL

143 framework called distributional  $RL^{36,37,41}$ . This algorithm allows an agent to learn the entire

144 probability distribution of rewards, instead of the expected value which is typically the learning

145 target in traditional RL algorithms (Fig. 1c). In distributional RL, an agent is equipped with a set 146 of value predictors ( $V_i$ ), where *i* corresponds to the index of the value predictor (or "value 147 neuron"). The value of the *i*-th neuron ( $V_i$ ) is updated based on the learning rates ( $\alpha_i^+, \alpha_i^-$ ) and 148 the RPE ( $\delta_i$ ) for that neuron *i*:

(3)

149

- 150  $V_i \leftarrow V_i + \alpha_i^+ \cdot \delta_i \quad if \ \delta_i > 0$
- 151  $V_i \leftarrow V_i + \alpha_i^- \cdot \delta_i$  if  $\delta_i < 0$
- 152

153 Similar to risk-sensitive RL, the learned value of each value predictor converges on estimates 154 larger or lower than the expected value, determined by the ratio between  $\alpha_i^+$  and  $\alpha_i^-$ .

155 Mathematically, each  $V_i$  converges on the  $\tau_i$ -th expectile of the distribution (Fig. 1c) where  $\tau_i$ 

156 (asymmetric scaling factor) is defined by:

158 Asymmetric scaling factor: 
$$\tau_i = \frac{\alpha_i^+}{\alpha_i^- + \alpha_i^+}$$
 (4)

159

Expectiles are the solutions to asymmetric least squares minimization and generalize the mean of a distribution (with the mean being the  $0.5^{\text{th}}$  expectile) as quantiles generalize the median (with the median being the  $0.5^{\text{th}}$  quantile)<sup>42</sup>. Since a set of expectiles can define a distribution, the diversity of  $\tau_i$  across the population enables learning of the entire probability distribution.

165 **Problem.** In both risk-sensitive RL and distributional RL, unbalance in learning rate parameters 166 for positive and negative RPEs gives rise to optimistic and pessimistic biases in learned values. 167 Importantly, however, the underlying biological mechanism regulating learning rate parameters 168  $(\alpha^+, \alpha^-)$  and asymmetry thereof  $(\tau)$  remains unclear.

169

170 In the following sections, we will discuss potential biological mechanisms that regulate

171 asymmetric learning rates ( $\alpha^+$ ,  $\alpha^-$ ). We will first modify the above RL algorithms to incorporate

172 important neural circuit architectures in the brain. We will then propose two key biological

173 mechanisms that can give rise to asymmetric learning rates (called Model 1 and 2). We will then

174 show that our model can explain previous experimental data and psychiatric conditions.

175

#### 176 Incorporating biological features into RL models

177 The above RL models provide algorithmic-level formulations, yet they do not recapitulate

178 fundamental characteristics of the neural circuits thought to perform RL in the brain $^{43-46}$ . We

179 next incorporate some of the important circuit and synaptic properties into the model.

180

181 In the brain, it is thought that dopamine neurons in the ventral tegmental area (VTA) broadcast

182 RPEs<sup>17</sup> and modulate synaptic plasticity in dopamine-recipient areas<sup>33,47</sup>. The striatum is the

183 major target of dopaminergic projections. It has been thought that spiny projection neurons

184 (SPNs) in the striatum represent values, and dopamine modulates plasticity of synapses on

SPNs<sup>33,34,47,48</sup> (Fig. 2a). Under this framework, the value representations in SPNs are updated by
dopaminergic RPEs. In most RL models, each value predictor is typically updated by both
positive and negative RPEs. If the value is computed based on a weighted sum of some inputs
(i.e., using linear function approximation<sup>11</sup>), the update rules described above (Eq 3 and 4) are
equivalent to performing a semi-gradient descent that minimizes RPEs<sup>11</sup> (see Methods).
The basic architectural assumptions of these RL models are, however, at odds with the RL

circuitry in the brain. Importantly, in the striatum, there are two major classes of dopaminerecipient SPNs characterized based on the type of dopamine receptor that they express: D1- or
D2-type dopamine receptors (D1R and D2R)<sup>48</sup>. SPNs expressing D1R and D2R constitute the socalled direct and indirect pathways and exert opposing effects on downstream "output" neurons,
with each pathway promoting or opposing a certain output (e.g., movement).

197

198 In addition to the presence of direct and indirect pathways, there are two additional properties in these opposing populations that need to be considered<sup>32</sup>. First, D1R and D2R have different 199 200 affinities to dopamine: high in D2R and low in D1R (EC<sub>50</sub> affinity constant is 1 µM for D1R and 201 10 nM for D2R) $^{49,50}$ . The dose-occupancy relationship of D1R and D2R are sigmoidal but they 202 are shifted with one another with respect to dopamine concentration (Fig. 2b). Importantly, at normal dopamine levels (approx. 50-100nM)<sup>51,52</sup>, D2Rs are mostly occupied while D1Rs are 203 204 mostly unoccupied (Fig. 2b). Although whether the affinities of D1R and D2R differ at the molecular level has been questioned<sup>53</sup>, a recent study showed that intracellular signaling through 205 206 protein kinase A (PKA) in D1- and D2-SPNs is triggered by a phasic increase and a decrease in 207 dopamine, respectively, in behaving animals<sup>35</sup>. These results are consistent with (apparent) difference in affinities of D1R and D2R assumed in previous studies<sup>49</sup>, although the exact reason 208 for the difference remains to be clarified<sup>53</sup>. 209

210

211 The second important property pertains to different learning rules in D1- and D2-SPNs which are 212 predicted from different affinities of the receptors. Consistent with the observed PKA signals in

these cells, recent studies have shown that glutamatergic inputs on D1-SPNs are potentiated by a

214 transient *increase* in dopamine, whereas those on D2-SPNs are potentiated by a transient

215 *decrease* in dopamine<sup>34,35</sup> (Fig. 2c), supporting opposing plasticity rules between D1- and D2-

216 SPNs.

217

- 218 There have been previous efforts to incorporate in RL models the direct and indirect pathways 219 (also called "Go" and "NoGo" pathways, respectively) such as Opponent Actor Learning (OpAL<sup>30</sup>, OpAL<sup>\*54</sup>) and Actor learning Uncertainty (AU)<sup>32</sup> models. These previous models 220 were developed as Actor-Critic models<sup>11</sup>. Here, we will build on the AU model to focus on the 221 222 problem of value learning and extend it to support risk-sensitive RL and distributional RL. Our 223 model has two separate populations of value predictors corresponding to D1R- and D2R-SPNs, 224 that store the quantities  $P_i$  and  $N_i$  respectively (Eq 6, Fig. 2d). Mimicking dopamine's effect on 225 potentiation,  $P_i$  or  $N_i$  will increase their estimates if an RPE is positive or negative, respectively, with the learning rates defined by  $\alpha_i^+$ ,  $\alpha_i^-$  (Eq. 6). Importantly, the value  $V_i$  can be obtained 226 227 simply by taking the difference between  $P_i$  and  $N_i$ . (Eq. 7).
- 228

229	D1R-SPN:	
230	$P_i \leftarrow P_i + \alpha_i^+ \cdot  \delta_i  - \beta \cdot P_i  if \ \delta_i \ge 0$	(5)
231	$P_i \leftarrow P_i - \beta \cdot P_i  if \ \delta_i < 0$	
232	D2R-SPN:	
233	$N_i \leftarrow N_i + \alpha_i^- \cdot  \delta_i  - \beta \cdot N_i  if \ \delta_i \leq 0$	
234	$N_i \leftarrow N_i - \beta \cdot N_i  if \ \delta_i > 0$	
235	Value: $V_i = P_i - N_i$	(6)

236

237 where  $\beta$  is a decay parameter which represents synaptic decay in the absence of RPEs. This

238 model (Eq 6 and 7) preserves various essential properties of the previous RL models: (1)

learning in *P* and *N* can be combined to provide a simple update rule for value *V*, and (2) this

240 update rule approximates the gradient descent that minimizes RPEs (when  $\beta = 0$ , the update rule

is equivalent to the gradient descent). Importantly, with  $\beta > 0$ , we can show that these simple

242 learning rules guarantee convergence of value, without the need for additional mechanisms to

243 modulate the learning rates over iterations (Methods 1.3).

244

For instance, in a stochastic environment where there is a probability p of receiving a reward of a fixed magnitude r = 1, the stochastic fixed point of the learned value  $V_i$  (i.e., convergence point) will be defined by Eq 7.

248

249 
$$V_{i} = \frac{\frac{\tau_{i}}{1-\tau_{i}} \frac{p}{1-p}}{\frac{\tau_{i}}{1-\tau_{i}} \frac{1-p}{1-p}+1+C} \cdot r \text{, where } C = \frac{\beta}{(1-p)\cdot(1-\tau)}$$
(7)

250

251 Note that Eq.7 contains an additional term *C* which depends on  $\beta$  and this decay factor  $\beta$  is 252 important to stabilize the  $P_i$  and  $N_i$  estimates (avoid infinite increases) (Methods, 1.3.1, Extended 253 Data Fig. 1).

254

This formulation now provides a mechanistic model suitable for risk-sensitive RL (when there is one value predictor) as well as distributional RL (when there are multiple value predictors), which incorporate the neural circuit architecture and plasticity rules of D1R- and D2R-SNPs found in the brain.

259

With this model at hand, we now discuss potential mechanisms that produce an asymmetry in 260 learning rates  $\alpha_i^+$ ,  $\alpha_i^-$ , which, in turn, causes biases in value predictions. In principle, learning 261 262 rate parameters can be a function of (1) the scaling of RPEs, i.e., the slope of dopamine 263 responses as a function of RPE ( $\delta$ ), and (2) the scaling of value updates, i.e., the efficacy of 264 dopamine-dependent synaptic plasticity at the level of SPNs. In the following, we discuss each 265 scenario, emphasizing the role of either tonic or phasic dopamine activity in each of these 266 mechanisms (Model 1 and 2, respectively). For simplicity, we will start with a model in which  $\alpha^+, \alpha^-$  are equal for all neurons within both P and N populations, equivalent to risk-sensitive 267

RL. We will then relax this assumption and introduce heterogeneity by allowing  $\alpha_i^+$ ,  $\alpha_i^-$  to vary 268 across neurons, implementing a form of distributional RL. 269

270

#### 271 Model 1: The role of baseline dopamine in asymmetric learning

272 As discussed above, D1R and D2R have different affinities to dopamine which leads to different 273 levels of receptors' occupancy at a given baseline dopamine level (Fig. 2b). Crucially, due to the 274 sigmoidal shape of the dose-occupancy curves, the slope of the curve changes with baseline 275 dopamine level, which means that a given dopamine transient leads to a different change in 276 receptor occupancy depending on the baseline dopamine level (Fig. 3a,b). That is, the receptors' 277 sensitivity changes with baseline dopamine (Fig. 3c). In addition, a key consequence of the 278 distinct receptors' affinities is that an increase and decrease in baseline dopamine will cause 279 opposite changes in the sensitivity of D1R and D2R. Specifically, an increase in dopamine will 280 decrease D1R sensitivity relative to D2R, whereas a decrease in dopamine will increase D2R 281 sensitivity relative to D1R (Fig. 3c,d).

282

283 Building on this insight in Model 1, we postulate that the learning rates for positive and negative 284 RPEs are a function of the D1R and D2R sensitivity, respectively. This is supported by previous 285 studies that have reported that the effect of dopamine transients of a given magnitude in SPNs' plasticity can be modulated by the level of dopamine baseline<sup>34</sup>. In addition, it has been reported 286 that the level of potentiation in SPNs<sup>33,34</sup> or plasticity, which are related to intracellular signals<sup>35</sup>, 287 288 scale with the magnitude of dopamine transients, keeping all else fixed. These observations can 289 be summarized with the following rule:

- 290
- $LTP_{D1} \approx \alpha^+ \cdot |DA_{hurst}|$
- $LTP_{D2} \approx \alpha^{-} \cdot |DA_{pause}|$ 291

Where  $\alpha^+, \alpha^-$  correspond to the receptors' sensitivities and depend on the dopamine baseline 292 293 level. This rule can be directly related to the update equations for the P and N populations in our 294 model:

 $\Delta P = \alpha^+ \cdot |\delta| \dots \text{ if } \delta \ge 0$ 295

296	$\Delta N = \alpha^{-} \cdot  \delta  \dots \text{if } \delta < 0$
297	
298	It can been shown that this learning rule is in agreement with the normative solution for the
299	problem of value learning <sup>11</sup> (Methods 1.6).
300	
301	In short, in Model 1, a shift in the baseline dopamine level causes asymmetries in scaling of the
302	value updates for positive versus negatives RPEs via the modulation of receptors' sensitivities,
303	which leads to value learning biases. This is a direct consequence of the dose occupancy
304	relationships of D1R and D2R (Fig. 3b-d).
305	
306	Model 2: Asymmetric scaling of phasic dopamine responses, inspired by distributional RL
307	In Model 2, we postulate that the learning rates $\alpha^+$ and $\alpha^-$ are a function of the scaling (i.e.,
308	'slope') of dopamine responses evoked by positive and negative RPEs, respectively:
309	$DA_{burst} = \alpha^+ \cdot \delta \dots \text{ if } \delta \ge 0$
310	$DA_{pause} = \alpha^- \cdot \delta \dots \text{if } \delta < 0$
311	This is supported by a previous study on distributional RL that demonstrated that individual
312	dopamine neurons vary in terms of how the magnitude of reward responses is scaled as a
313	function of positive and negative RPEs (Fig. 3e) <sup>36</sup> .
314	
315	In the distributional RL framework, individual dopamine neurons vary in terms of their
316	asymmetric scaling factor $\tau_i$ and each of the multiple value predictors ( $V_i$ ) converges on the $\tau_i$ -th
317	expectile of the reward distribution (Eq. 4). However, in most applications of distributional RL,
318	action selection is still based on the expected value of the reward distribution. Thus, the quantity
319	relevant to action selection can be described using the population level average $\tau_{population}$ , and
320	biased value learning at the behavioral level could arise if $\tau_{population}$ is higher or lower than 0.5.
321	This can occur from a differential loss of optimistic or pessimistic dopamine neurons. Another
322	possibility is an overall upward or downward shift in the distribution of $\tau_i$ across the population
323	due to, for example, intrinsic factors modulating the gain of dopamine phasic responses.

324

Risk-sensitive RL can be thought of as a special case of distributional RL which has only one value predictor. Here, the slope of the average dopamine evoked transient to positive and negative RPEs, may correspond to the population level learning rates for positive and negative RPEs ( $\alpha^+$ ,  $\alpha^-$ ), respectively. If the asymmetric scaling factor  $\tau$  is higher or lower than 0.5, value learning will be biased (Fig. 3e).

330

#### 331 Testing for evidence of either model in experimental data

#### 332 *Tian and Uchida* (2015).

333 We next examined whether Model 1 or 2 can explain empirical data obtained in experimental 334 animals or humans. We first examined the data obtained in mice in our previous study<sup>55</sup>. In this 335 study, the authors tested the effect of lesioning the habenula, a brain structure implicated in 336 depression<sup>56–58</sup>, on the activity of dopamine neurons and on reward-seeking behavior. Head-fixed 337 mice were trained in a Pavlovian conditioning task in which odor cues predicted reward with 338 different probabilities (10%, 50%, 90%). After performing habenula (n=5) or sham (n=7) lesions 339 (Fig. 4a), the spiking activity of VTA dopamine neurons was recorded while mice performed the 340 task.

341

342 After lesions, mice exhibited an elevated reward-seeking behavior (anticipatory licking) in 343 response to cues predictive of probabilistic rewards, consistent with an optimistic bias in reward 344 expectation (Fig. 4b, right). Importantly, anticipatory licking gradually increased over several 345 sessions after lesions, suggesting that the optimistic bias developed through learning (Fig. 4b, 346 left). To bring insight into the underlying cause of these biases, we fit two different RL models to 347 the anticipatory lick responses on a trial-by-trial basis (Extended Data Fig. 2), assuming a linear 348 relationship between value predictions and anticipatory licking. These models considered either a 349 change in the sensitivity to rewards (Extended Data Fig. 2b) or asymmetric learning rates 350 (Extended Data Fig. 2c). This analysis showed that the biases observed in the behavior could be 351 explained by asymmetric learning rates, but not by reward sensitivity because the reward

sensitivity was unchanged in the lesion group with respect to the control group (Extended DataFig. 2c).

354

355 Dopamine neurons' responses to reward-predictive cues reflect the increases in value expectation 356 predicted by the cue with respect to baseline. The overall magnitudes of cue-evoked responses 357 were not elevated in lesioned animals compared to control animals (Fig. 4d). However, the shape 358 of the response curve indicated an 'optimistic' bias: although in control animals, cue responses 359 scaled linearly with the expected value (i.e., reward probability), the response function of the 360 lesioned animals was convex. In other words, in control animals the response to the 50%-reward 361 cue was not significantly different from the quantity that results from the linear interpolation 362 between the responses to 10%- and 90%-reward cues. In lesioned animals, however, the response 363 to the 50%-reward cue was significantly greater than this quantity, which is indicative of an 364 optimistic bias in value predictions (Fig. 4d, see Methods 1.3.3 for analysis of value predictions 365 curve convexity). Such a change was observed at the level of the population average. Further 366 analysis using individual neurons showed that when calculating a single-cell level metric that 367 compares the 50%-reward cue to the same linear interpolation point, there was a broad 368 distribution in this metric below and above the interpolated point both in the control and lesion 369 groups (Fig. 4e-f). The distribution was, however, shifted in its mean in the lesion group (Fig. 370 4e). These analyses indicated that both anticipatory licking and dopamine cue responses have an 371 optimistic bias as characterized by an overvaluation of probabilistic rewards, without still 372 pointing to the underlying mechanism.

373

### 374 Model 2 cannot explain the optimistic biases in behavior and cue-evoked dopamine

375 **responses after Hb lesions** 

376

In Model 2, an optimistic bias in reward expectation can arise if the average of the asymmetric scaling factor at the population level ( $\tau_{population}$ ) becomes greater than 0.5 (Fig. 5a,b).

379

380 To test this idea, we obtained the asymmetric scaling factors  $(\tau_i)$  from dopamine neurons based 381 on their outcome responses: for each neuron, we constructed outcome response functions against 382 the magnitude of RPEs (Fig. 5c, Extended Data Fig. 3a,b). The response functions were obtained 383 based on (1) whether reward was delivered (positive RPEs) or not (negative RPEs), and on (2) 384 the magnitude of the reward expectation given by the reward probabilities predicted by each cue 385 (0.1, 0.5, 0.9) (Extended Data Fig. 3a,b). We then obtained the point at which the responses are more likely to be below or above baseline (i.e., 'zero-crossing points')<sup>36</sup> (Extended Data Fig. 3c), 386 and computed  $\alpha_i^+$  and  $\alpha_i^-$  as the slopes of the responses in the positive and negative domains 387 388 with respect to this zero-crossing point (Extended Data Fig. 3d), respectively. In both control and 389 lesioned animals, asymmetric scaling factors tiled a wide range between 0 and 1 and presented 390 other signatures consistent with distributional RL<sup>36</sup> (Extended Data Fig.4). Nonetheless, although the variance of the distribution of asymmetric scaling factors was greater in lesioned animals, the 391 mean did not change, indicating a lack of bias between  $\alpha_i^+$  and  $\alpha_i^-$  at the population level (Fig. 392 393 5d). This was also the case when the asymmetric scaling factor was derived directly from the 394 population average response (Fig. 5c). Thus, contrary to the conclusion in our previous study<sup>15</sup>, 395 these analyses indicated that changes in reward responses (and the resulting scaling factor  $\tau$ ) do 396 not explain the optimistic biases in behavior nor cue responses in lesioned animals (Fig. 5e,f). 397

# 398 Model 1 can explain the optimistic biases in behavior and cue-evoked dopamine responses 399 by Hb lesion

In addition to changes in the magnitude of dopamine RPEs, we observed that the baseline firing rates of dopamine neurons were elevated in lesioned animals (Fig. 6a). According to Model 1, if these changes are followed by an increase in the baseline dopamine levels in the striatum, this should give rise to biased value learning ( $\alpha^+ > \alpha^-$ ) and an optimistic bias in value expectation. In this way, this change in baseline firing can explain optimistic biases observed in lesioned animals. However, it remains unclear whether the observed change in baseline firing can result in functionally relevant levels of changes in the receptor occupancies discussed above.

407

408 To quantitatively predict dopamine concentrations in the striatum and resulting receptor 409 occupancies of D1R and D2R, we used a biophysical model commonly used in the field<sup>59</sup> 410 (Fig.6a). This model has the firing rate of dopamine neurons as its input, and considers diffusion 411 of dopamine, dopamine reuptake, and D2-autorreceptor-mediated inhibition of dopamine release 412 to predict the dopamine concentration in the striatum (Fig. 6b,e). In addition, it considers the 413 affinities of D1R and D2R to estimate their occupancy levels (Fig. 6c.f). After estimating these 414 two variables (dopamine concentration and receptor occupancy), we derived the receptor 415 sensitivities (Fig. 6g-h). The receptor sensitivities were quantified as the slope of the resultant 416 changes in receptor occupancy given the observed baseline and phasic responses of dopamine neurons. We then trained Model 1 using the receptor sensitivities as learning rates ( $\alpha^+$  and  $\alpha^-$ ) 417 418 for both control and lesioned animals. 419 420 The biophysical model indeed supported that the observed change in dopamine neuron firing can 421 cause a significant increase in dopamine concentration (Fig. 6e) and in D1 and D2 receptor 422 occupancies at baseline (Fig. 6g). These changes are expected to cause a significant asymmetry 423 in receptor sensitivities favoring D1 receptors over D2 receptors (Fig. 6h-i). 424 425 These receptor sensitivities were directly used as the asymmetric learning rates in a temporal-426 difference (TD) learning version of Model 1 (see Methods 1.3, 3.3). After training, the model incorporating the predicted asymmetries in learning rates ( $\alpha^+, \alpha^-$ ) produced optimistic biases in 427 428 value predictions and in normalized cue responses, similar to those observed in lesioned animals 429 (Fig. 6k-l). The model simulating control animals developed no significant biases. 430 431 Additionally, the overall decrease in the magnitude of cue responses, observed in lesioned 432 animals, was reproduced in Model 1 using TD learning (Fig. 6k). This occurs because TD 433 learning calculates RPEs based on the change in values between before and after cue 434 presentation, and the "baseline" (pre-cue) reward expectation was also increased by optimistic 435 value learning (Fig. 6k). These results, together, indicate that Model 1 provides a parsimonious

436	account of the data: a change in baseline firing of dopamine neurons, rather than changes in
437	phasic responses, is the likely mechanism that led to optimistic biases in reward-seeking
438	behavior as well as cue-evoked dopamine responses in habenula lesioned animals.
439	
440	Model 1 and model 2 play complementary roles in the encoding of asymmetric learning
441	rates
442	Although Model 2 did not explain the optimistic biases in the data in habenula-lesioned mice, the
443	distributional RL version of Model 2 explained other features of the data (Extended Data Fig. 3-
444	4). As mentioned, in both control and lesioned animals, asymmetric scaling factors tiled a wide
445	range between 0 and 1 <sup>36</sup> (Extended Data Fig.4). Furthermore, cue-evoked responses of individual
446	neurons showed a wider distribution than what is expected by noise (Figure 4d). Finally, the core
447	prediction of distributional RL – a positive correlation between the asymmetric scaling factors of
448	the RPE responses of individual dopamine neurons and their zero-crossing points <sup>36</sup> – was also
449	present in controls and after Hb lesions. Together these results support that the basic features of
450	distributional RL are present in a way consistent with Model 2.

451

452 To complement this analysis, we tested whether Model 2 could have explained the signatures of 453 the data if asymmetric scaling factors  $(\tau)$  derived from dopamine responses were indeed overall 454 biased (Extended Data Fig. 5). As expected from the model's fixed-point analysis (Methods 1.3), 455 if we imposed a shift in the mean of the distribution of asymmetric scaling factors (i.e.,  $\tau_{population} > 0.5$ ), the value predictors indeed exhibited optimistic biases (Extended Data Fig. 456 457 5e,f). However, the model did not reproduce the optimistic bias in cue-induced TD errors 458 observed in the data (Extended Data Fig.5g,h). This is due to an interaction of the biases in 459 prediction at "baseline" (pre-cue) and the cue, together with the optimistic asymmetry in the 460 scaling of the TD errors at cue themselves. Importantly, this was found in both versions of Model 461 2, distributional and risk-sensitive RL (Extended Data Fig. 5a-d and e-h). The difficulty of 462 explaining biased dopaminergic cue responses further makes the Model 2 an unlikely mechanism 463 to explain the optimistic biases in the data.

#### 464

465	Altogether the data supports a model in which the mechanisms of Model 1 and 2 play
466	complementary roles in the encoding of asymmetric learning rates. The mechanism of Model 2
467	explains the variability in single neuron responses, consistent with the expectile code in
468	distributional RL. On the other hand, the mechanism of Model 1 at the population level,
469	generating asymmetries in learning rates and biases in value expectations, which might require
470	context-dependent regulation <sup>60</sup> .
471	
472	Taken together, the above results suggest that Model 1 and 2 coexist in the brain. This can be
473	formalized as follows:
474	
475	$P_i \leftarrow P_i + \hat{\alpha}_i^+ \cdot \delta_i \dots \text{if } \delta_i \le 0$
476	$N_i \leftarrow N_i + \hat{\alpha}_i^- \cdot \delta_i \dots \text{if } \delta_i < 0$
477	where:
478	$\widehat{\alpha}_i^+ = \alpha_P \cdot \alpha_i^+$
479	$\hat{lpha}_i^- = lpha_N \cdot lpha_i^-$
480	
480 481	where $\alpha_i^+$ and $\alpha_i^-$ correspond to the asymmetric scaling of dopamine RPEs at the single-cell level
480 481 482	where $\alpha_i^+$ and $\alpha_i^-$ correspond to the asymmetric scaling of dopamine RPEs at the single-cell level (Model 2) and $\alpha_P$ and $\alpha_N$ correspond to the asymmetric scaling of synaptic plasticity in D1R and
<ul><li>480</li><li>481</li><li>482</li><li>483</li></ul>	where $\alpha_i^+$ and $\alpha_i^-$ correspond to the asymmetric scaling of dopamine RPEs at the single-cell level (Model 2) and $\alpha_P$ and $\alpha_N$ correspond to the asymmetric scaling of synaptic plasticity in D1R and D2R at the population level (Model 1).
<ul> <li>480</li> <li>481</li> <li>482</li> <li>483</li> <li>484</li> </ul>	where $\alpha_i^+$ and $\alpha_i^-$ correspond to the asymmetric scaling of dopamine RPEs at the single-cell level (Model 2) and $\alpha_P$ and $\alpha_N$ correspond to the asymmetric scaling of synaptic plasticity in D1R and D2R at the population level (Model 1).
<ul> <li>480</li> <li>481</li> <li>482</li> <li>483</li> <li>484</li> <li>485</li> </ul>	where $\alpha_i^+$ and $\alpha_i^-$ correspond to the asymmetric scaling of dopamine RPEs at the single-cell level (Model 2) and $\alpha_P$ and $\alpha_N$ correspond to the asymmetric scaling of synaptic plasticity in D1R and D2R at the population level (Model 1). Linking asymmetric learning and baseline dopamine levels in healthy subjects
<ul> <li>480</li> <li>481</li> <li>482</li> <li>483</li> <li>484</li> <li>485</li> <li>486</li> </ul>	where $\alpha_i^+$ and $\alpha_i^-$ correspond to the asymmetric scaling of dopamine RPEs at the single-cell level (Model 2) and $\alpha_P$ and $\alpha_N$ correspond to the asymmetric scaling of synaptic plasticity in D1R and D2R at the population level (Model 1). Linking asymmetric learning and baseline dopamine levels in healthy subjects <i>Cools et al.</i> , (2009) <sup>24</sup> .
480 481 482 483 484 485 486 486 487	where $\alpha_i^+$ and $\alpha_i^-$ correspond to the asymmetric scaling of dopamine RPEs at the single-cell level (Model 2) and $\alpha_P$ and $\alpha_N$ correspond to the asymmetric scaling of synaptic plasticity in D1R and D2R at the population level (Model 1). <b>Linking asymmetric learning and baseline dopamine levels in healthy subjects</b> <i>Cools et al., (2009)</i> <sup>24</sup> . There have been very few studies that examined the relationship between baseline dopamine
480 481 482 483 484 485 486 487 488	where $\alpha_i^+$ and $\alpha_i^-$ correspond to the asymmetric scaling of dopamine RPEs at the single-cell level (Model 2) and $\alpha_P$ and $\alpha_N$ correspond to the asymmetric scaling of synaptic plasticity in D1R and D2R at the population level (Model 1). <b>Linking asymmetric learning and baseline dopamine levels in healthy subjects</b> <i>Cools et al., (2009)</i> <sup>24</sup> . There have been very few studies that examined the relationship between baseline dopamine levels and asymmetry in learning from positive and negative outcomes. As a rare case for such
480 481 482 483 484 485 486 487 488 489	where $\alpha_i^+$ and $\alpha_i^-$ correspond to the asymmetric scaling of dopamine RPEs at the single-cell level (Model 2) and $\alpha_P$ and $\alpha_N$ correspond to the asymmetric scaling of synaptic plasticity in D1R and D2R at the population level (Model 1). <b>Linking asymmetric learning and baseline dopamine levels in healthy subjects</b> <i>Cools et al., (2009)</i> <sup>24</sup> . There have been very few studies that examined the relationship between baseline dopamine levels and asymmetry in learning from positive and negative outcomes. As a rare case for such examinations, Cools et al. <sup>24</sup> provided intriguing data in humans. They compared the performance

491 capacity is estimated by injecting the positron emission tomography (PET) tracer

<sup>18</sup>F]fluorometatyrosine (FMT) and is thought to be correlated with baseline dopamine levels<sup>61,62</sup>.
This study found that higher dopamine synthesis capacity was correlated with better learning
from gains but not with learning from losses (Fig. 7b). As a result, in reversal learning, subjects
with higher dopamine synthesis capacity learned from gains than losses, reported as the 'relative
reversal learning (RRL)' index in their study (Fig. 7b). This result, thus, provides direct evidence
supporting our Model 1.

498

499 In addition, they found that dopamine synthesis capacity predicts the effectiveness of

500 bromocriptine (D2 partial agonist) in altering learning rate asymmetry: bromocriptine's ability to

501 bias learning from gains over losses (i.e., positive change in RRL) was negatively correlated with

502 dopamine synthesis capacity (Fig. 7c). We found that this result can also be explained by Model

503 1. For this, we simulated the effects of bromocriptine with the biophysical model used above,

and derived the asymmetric learning rates from the slopes of the D2R occupancy (Fig. 7d,

505 Extended Data Fig. 6a,b) or activation curves (Fig. 7d, Extended Data Fig. 6c,d). The RRL

506 parameter reported by Cools et al. corresponds to the asymmetric scaling factor  $\tau$ , and is

507 equivalent to  $(2\tau - 1)$  (as described in the Methods 4.1). We then computed what would be the 508 change in this parameter Δ $(2\tau - 1)$  induced by bromocriptine (Fig. 7e-f, Extended Data Fig. 6e-

509

1).

510

511 This analysis revealed that by considering the asymmetries in learning rates induced by changes 512 in the baseline occupancy of the receptors, our model can capture their results in a qualitative 513 manner. Intuitively, the less dopamine there is at baseline, the lower the occupancy of D2R at 514 placebo conditions. This leads to a larger increase in D2R occupancy induced by D2 agonist in 515 low dopamine baseline conditions (Fig. 7d, Extended Data Fig. 6a) and, thus, a larger increase in 516 asymmetry in learning form gains over losses, if D1R occupancy is kept fixed These effects still 517 hold even if we consider, in addition to bromocriptine's effects in postsynaptic receptors (D2 518 long or D2l), its effect on inhibition of dopamine release via presynaptic (D2 short or D2s) 519 autoreceptors<sup>63,64</sup> (Fig. 7d, Extended Data Fig. 6b). This can be simulated as a decrease in

dopamine level, which leads to a shift in the occupancy curves to the right. Finally, we can consider effect of the *partial* agonism of the drug, that leads to a lower activation level of receptors even if the occupancy is maximal (Fig. 7d, Extended Data Fig. 6c-d). Even after considering this last factor, the results remain qualitatively the same as those found in the original study. These results were robust to a relatively wide range of values in the simulation's parameters (Extended Data Fig. 7, 8).

526

#### 527 Linking psychiatric conditions to baseline dopamine levels

528 *Timmer et al.*, 2018

529 Various psychiatric disorders are characterized by abnormal future predictions or mood. Our 530 Model 1 raise the possibility that an overall decrease in baseline dopamine level in the striatum 531 would enhance learning from negative outcomes over learning from positive outcomes leading to 532 persistent pessimistic future value expectations, a hallmark of depressive-like symptoms (Fig. 533 3a,b). A piece of evidence supporting this in the human literature is the greater learning rates for losses over gains in patients with Parkinson's disease (PD)<sup>22,25</sup>, its comorbidity with 534 depression<sup>25,65</sup> that can precede the PD diagnosis<sup>65–67</sup>, and the reports of decreased dopamine 535 536 transporter binding in the ventral striatum in depressed PD patients compared to non-depressed PD patients<sup>68,69</sup>. 537

538

In addition, the progression of dopaminergic axonal loss in PD is topographically unbalanced: 539 the axonal loss is more prominent in the dorsal striatal regions<sup>70</sup> than in the ventral ones. This 540 541 leads to uneven dopamine baseline levels across the striatum that would interact with the global 542 increases in dopamine induced by dopaminergic medications in PD patients. We hypothesize that 543 a behavioral readout of the degree of this unevenness might be the presence or absence of 544 depression as a comorbidity: *patients with depression might have lower dopamine levels in the* 545 *ventral striatum.* Thus, if indeed baseline dopamine levels are correlated with depression, this 546 comorbidity could be predictive of the effects of PD medication.

547

548 We examined a previous study that provided evidence for this hypothesis <sup>71</sup>. Here, PD patients 549 with and without depression history were tested in a gambling task, under presence or absence of 550 medication ('ON' and 'OFF' medication states). The authors fitted a 'loss aversion' parameter to 551 the behavioral performance, which is equivalent to  $1 - \tau$  in our model, under some assumptions 552 (Methods). Their results were consistent with our model predictions. In the OFF-medication 553 state, there was a (near-significant) main effect of depression group (with or without depression) 554 on the learning rate asymmetry: patients with a depression history tended to be more loss averse 555 than nondepressed patients (P = 0.052). This is consistent with a decrease of dopamine levels in the ventral striatum and thus a regime of  $\alpha^+ < \alpha^-$  in value learning. Importantly, in the ON-556 557 medication state, the medication effects on the asymmetry in learning rates were predicted by the 558 degree of severity of depression: patients with larger depression scores exhibited greater drug-559 induced decreases in loss aversion (Fig. 7g), which would correspond to an increase in  $\tau =$  $\frac{\alpha^+}{\alpha^++\alpha^-}$  in our model This is consistent with our Model 1: higher degrees of depression might be 560 correlated with lower levels of baseline dopamine, making the D1R sensitivity more susceptible 561 562 to an artificial increase in baseline dopamine with L-DOPA medication (Fig. 7h; further details 563 discussed in Methods). 564

565

#### 566 **Discussion**

567

A hallmark of various psychiatric disorders is overly optimistic or pessimistic predictions about the future. Using RL models, we sought to identify potential biological mechanisms that give rise to biased value predictions, with a particular focus on the roles of phasic versus tonic dopamine. Our results demonstrate that variations in tonic dopamine levels can modulate the efficacy of synaptic plasticity induced by positive versus negative RPEs, thereby resulting in biased value learning (Model 1). This effect arises due to sigmoidal shapes of the dose-occupancy curves and different affinities of dopamine receptors (D1R and D2R); alterations in the tonic dopamine level

575 result in changes in the slope of the dose-occupancy curve (and thus, sensitivity) of dopamine 576 receptors at the baseline dopamine concentration. We show that this mechanism offers a simple 577 explanation for how changes in tonic dopamine levels can result in biased value learning in a few 578 examples of value learning in mice and humans. Additionally, we show that this mechanism may 579 underlie symptoms of various psychiatric and neurological disorders. Although altered phasic 580 dopamine responses could have been a natural suspect as a candidate mechanism for biased 581 value learning<sup>37,38</sup>, our study provides a novel mechanism; the interaction between tonic and 582 phasic dopamine can give rise to biased value learning, even when phasic dopamine responses 583 remain relatively unchanged.

584

#### 585 The impact of properties of dopamine receptors on reinforcement learning (RL)

586 Our results highlight the importance of considering properties of dopamine receptors and neural 587 circuit architecture (i.e., direct and indirect pathways) in RL models. Based on different affinities 588 of dopamine D1 and D2 receptors, it has been proposed that D1- and D2-SPNs play predominant 589 roles in learning from positive and negative dopamine responses<sup>32,72–75</sup>. In support of this idea, 590 recent experiments have demonstrated that PKA signaling in D1- and D2-SPNs is primarily driven by a phasic increase and decrease of dopamine, respectively<sup>35</sup>. Furthermore, LTP-like 591 592 changes in D1- and D2-SPNs are triggered by a phasic increase and decrease of dopamine, 593 respectively<sup>33,34</sup>. These recent pieces of evidence suggest that these plasticity rules are a basic 594 principle of the RL circuitry in the brain. Here we explored the properties of this RL model and 595 found the impact of the shape (slope) of receptor occupancy curves and showed that the tonic 596 dopamine levels can modulate the relative efficacy of learning from positive versus negative 597 RPEs.

598

599 One assumption in our model is that after a change in the tonic dopamine level, intracellular 600 signaling reaches a steady inactive state, and it is the *change* in receptor occupancy that matters 601 for inducing synaptic plasticity, rather than the *absolute* level of receptor occupancy reached 602 during phasic dopamine responses. We note that absolute level might also contribute, yet it is

expected that an increase or decrease in absolute occupancy levels will cause effects in the samedirection as the effects of relative change that we explored in this study.

605

606 Additionally, our model, which incorporates the new plasticity rules, the opponent circuit 607 architecture and properties of D1/D2 dopamine receptors, provides insights into the basic design 608 principle of the brain's RL circuit. It should be noted that the dose occupancy curves were 609 plotted as a function of the logarithm of dopamine concentration, which makes the occupancy 610 curves into sigmoidal shapes (Fig. 3, Extended Data Fig. 9). This logarithmic scaling is 611 important in two ways. First, considering two sigmoidal curves for D1R and D2R together, the 612 curves are approximately symmetric around the normal baseline dopamine level (Fig. 3a, 613 Normal). Second, logarithmic scaling means that a fold-change in dopamine concentration will 614 lead to the same leftward or rightward shift in these plots. It has long been argued that signaling 615 of RPEs by dopamine neurons is curtailed by the fact that dopamine neurons have relatively low 616 firing rates (2-8 spikes per second), and inhibitory responses of dopamine neurons tend to be 617 smaller than excitatory responses<sup>76,77</sup>. Importantly, if we consider logarithmic scaling of 618 dopamine concentration, the problem of this asymmetry is substantially mitigated (Extended 619 Data Fig. 10). For example, with the baseline firing of 6 spikes per second, a phasic increase to 620 18 spikes per second and a phasic decrease to 2 spikes per second will cause the identical *fold*-621 changes in spiking (i.e., 3-fold changes in both directions), which would lead to a similar fold-622 changes in dopamine levels (Extended Data Fig. 11) and similar percent increase and decrease in 623 receptor occupancy in D1R and D2R, respectively (Fig. 3a). Consequently, the system achieves 624 symmetry in its response to positive and negative dopamine responses of observed magnitudes. 625

This may help understand *why* the basal ganglia circuit employs the opponent circuit architecture in the first place. In the model used in the present study, the value is encoded as the difference between the activity of D1- and D2-SPNs (V = P - N)<sup>32</sup>. We propose that this opponent circuit architecture, together with the logarithmic scaling of dopamine concentration, allows the system to effectively learn and encode both positive and negative values, which are contributed by the

increase of firing in D1- and D2-SPNs, respectively. This would allow to expand the dynamic
range of value coding, without requiring high baseline firing rates. Thus, at the normal dopamine
baseline, learning from positive and negative dopamine responses is well balanced. When the
tonic dopamine level deviates from the normal level, however, then the symmetry is broken and
value learning becomes biased, as explored in the present study.

636

#### 637 The role of tonic dopamine levels in psychiatric disorders

As mentioned above, our modeling results provide an account for biased value predictions
observed in various psychiatric and neurological conditions. For one, our model provides a link
between findings in depressive-like states in animal models and the value learning biases
exhibited by humans.

642

643 In a rodent model of depression, it has been reported that spontaneous activity of dopamine neurons is decreased<sup>78</sup> (but see<sup>79,80</sup>). In addition, decreased spontaneous firing of dopamine 644 645 neurons has been observed as a result of chronic pain-induced adaptations that correlate with 646 anhedonia-like behavior<sup>81</sup>. Furthermore, maternal deprivation, which increases susceptibility to anhedonia, led to an upregulation of D2R expression in the VTA<sup>82</sup>, which is expected to decrease 647 648 the excitability of dopamine neurons via its autoreceptor function. Finally, chronic 649 administration of corticosteroids, a method to mimic anxiety and anhedonia-like states, results in 650 an increase in somatodendritic dopamine concentration which then decreases dopamine excitability via D2R hyper-activation<sup>83</sup>. These results of decreased dopamine excitability 651 652 correlated with anhedonia-like states are consistent with findings of increased burst firing of 653 lateral habenula (LHb) neurons<sup>56</sup> and potentiation of glutamatergic inputs onto the habenula<sup>57</sup> in 654 depression models. This is further supported by reports that depressive-like behavioral phenotypes can be ameliorated by optogenetic activation of dopamine neurons<sup>84</sup> and the anti-655 depressant effects of ketamine might be mediated by the inhibition of bursting in the LHb<sup>58</sup> 656 657

658 The mechanism by which a broad change in dopamine excitability could lead to depressive-like 659 states remains to be revealed. Just by assuming that a decrease in spontaneous firing leads to a 660 decrease in baseline dopamine level in the striatum, our model readily predicts that learning from 661 negative outcomes will be emphasized over learning from positive outcomes (Fig. 3a,b), as has 662 been reported in some studies of patients with major depressive disorder (MDD)<sup>1</sup>. In addition, 663 RL agents learning in these conditions exhibit enhanced risk-aversive behavior, pessimistic 664 outcome expectations, and increased sensitivity to losses compared to gains, all of which are signatures of depressive-like conditions<sup>1,5,21,85,86</sup>. This contrasts with findings of increased 665 dopamine synthesis capacity in pathological gambling patients<sup>87</sup>, who show the opposite 666 behavioral signatures<sup>3</sup>. 667

668

669 An additional line of research relevant to our proposal is PD patients and pathological gambling 670 as a comorbidity. Previous work has emphasized the interaction between the degree of dopaminergic loss and the effects of PD medications<sup>88–90</sup>, which can sometimes result in the 671 672 development of addictive disorders such as pathological gambling. As mentioned, the loss of 673 dopaminergic axons in PD patients has been reported to happen predominantly in the dorsal regions of the striatum<sup>70</sup>. Thus, at the onset of the motor impairment symptoms, which is when 674 675 L-DOPA medication tends to be prescribed, dopamine level is expected to be low in the dorsal 676 striatum while it might be relatively intact in the ventral striatum. This can lead to 'overdose' of 677 dopamine by medication: while L-DOPA might take dopamine levels in the dorsal striatum back 678 to its original set-point, it might cause an 'overdose' in the ventral striatum<sup>89,91</sup>. Our model 679 predicts that this overdose would lead to decreases in D2R sensitivity relative to D1R. Assuming 680 that the ventral striatal regions have a dominant role in value learning, this would result in 681 excessive optimistic expectations and risk seeking, two key behavioral features of pathological 682 gambling and addictive disorders. We provided indirect evidence for this hypothesis; future work 683 should directly test these predictions.

684

It should be noted that we did not consider changes in dopamine receptors density, which have also been related to value learning biases<sup>92</sup> and psychiatric conditions<sup>93</sup>. Future studies should explore the influence of this additional factor in the encoding of asymmetric learning rates (i.e.,  $(\hat{\alpha}_i^+, \hat{\alpha}_i^-)$ ).

689

#### 690 Tonic dopamine as a modulator of 'mood'

691 Mood refers to a person's emotional state as it relates to their overall sense of well-being.

692 Although the exact neural substrate of mood remains unknown, recent studies have indicated that

mood reflects not the absolute goodness of outcomes but rather on the discrepancy between

actual and expected outcomes in recent history $^{13,14}$ . That is, mood depends on the cumulative

695 sum of RPEs that occurred recently<sup>13</sup>. It has also been proposed that mood, in turn, affects the

696 way we perceive and learn from positive and negative outcomes  $(RPEs)^{13}$ .

697

698 Our model provides a unified mechanism for these two aspects of mood; both subjective feeling 699 of mood and biased learning from positive versus negative outcomes can arise from changes in 700 baseline dopamine levels which can be modulated by recent history of phasic dopamine 701 responses. It was proposed that this history dependent modulation of learning is an adaptive 702 mechanism that allows organisms to adapt quickly to slow changes in environments based on the 703 "momentum" of whether the situation is changing in a better or worse direction on a slow timescale (e.g. seasonal change)<sup>13,14</sup>. The models presented in the present study may provide 704 705 mechanistic insights into such mood-dependent modulation of learning and perception.

706

#### 707 Neural circuits for distributional reinforcement learning (RL)

We examined the possibility that optimistic biases in reward seeking behavior and dopamine cue responses observed in habenula-lesioned mice can be explained by Model 2, either based on risksensitive RL (the average response) or distributional RL (responses of a diverse set of individual dopamine neurons). We did not find evidence supporting this possibility. However, the present study makes two important contributions with respect to distributional RL. First, we can show

713	that our model, which incorporated direct and indirect pathway architecture, can support
714	distributional RL (Extended Data Fig. 12, 13). It would be interesting to examine what additional
715	features and functions could be gained by having this opponent architecture. Second, we largely
716	replicated the previous results <sup>36</sup> using an independent data set. That is, the signatures of
717	distributional RL were present in this data set (Extended Data Fig. 3-4), and dopamine cue-
718	evoked responses did show an optimistic bias. This provides further evidence for a distributional
719	code in dopamine neurons, and shows that there is an overall elevated distributional
720	representation in dopamine cue responses in habenula lesioned animals.
721	

#### 722 Concluding remarks

Taken together, our biologically inspired RL model provides a foundation to link findings in the

brain and formal models of RL. Our work highlights a causal impact of baseline dopamine on

biasing future value predictions, which may underlie mood and some abnormalities observed in
psychiatric patients and could be used to regulate risk sensitive behavior.

727

### 729 Methods

#### 730 **1. Reinforcement learning model**

Here we provide formal definitions and the framework of reinforcement learning used in this study. We have focused our model formulations to the problem of *prediction*, in which an agent learns to predict the value function<sup>11</sup>. The problem of *control* (the problem of how an agent selects and executes actions) is not considered. In RL, an agent's objective is to maximize the total cumulative rewards. It does so by learning the value associated with each state in an environment. For now, we will develop the model dropping the dependency on time within each episode. Here, the target to learn is the value function as defined by

737 
$$V(s_i) \coloneqq \mathbf{E}[r^{(n)}|s^{(n)} = s_i]$$

738 Where  $r^{(n)}$  is the reward experienced in the episode *n* (i.e., trial) of visiting state  $s_i$ . Learning of V(s) is 739 driven by reward prediction errors (RPEs,  $\delta$ ), the discrepancy between the actual and expected reward:

$$\delta^{(n)} = r^{(n)} - V(s_i)$$

741 The value is updated for the experienced state according to:

742 
$$V^{(n+1)}(s_i) \leftarrow V^{(n)}(s_i) + \alpha \cdot \delta^{(n)}$$

This is also known as the Rescorla-Wagner (RW) delta rule<sup>94</sup>. The reward in each trial is sampled from a reward distribution specific to a given state:  $r^{(n)} \sim R(s_i)$ . With the learning rule above, the value converges on the expected value of this reward distribution. This can be shown with a stochastic fixedpoint approach; the convergence point is derived by obtaining the value of  $V(s_i)$  at which the change in  $V(s_i)$  from trial *n* to trial (*n* + 1) is expected to be zero (i.e., is zero on average):

748 
$$\mathbf{E}[V^{(n+1)}(s_i) - V^{(n)}(s_i)] = 0$$

749 
$$\mathbf{E}[\alpha \cdot \delta^{(n)}] = 0$$

750 
$$\mathbf{E}[\alpha \cdot (r^{(n)} - V(s_i)] = 0$$

751 
$$\alpha \cdot \mathbf{E}[r] - \alpha \cdot \mathbf{E}[V(s_i)] = 0$$

752 
$$\mathbf{E}[V(s_i)] = \mathbf{E}[r_t]$$

$$V^*(s_i) = \mathbf{E}[r_t]$$

Where  $V^*(s_i)$  is the stochastic fixed-point: the value around which  $V(s_i)$  is expected to fluctuate after learning and corresponds to the learning target above.

#### 756 **1.1. Temporal difference learning**

Now we will consider time and extend the models to the temporal difference (TD) learning framework<sup>11</sup>.

758 Dopamine responses have been shown to present key signatures of TD errors<sup>95</sup>. Therefore, TD learning

models allow us to directly link the model variables to dopamine neural responses.

760 We can derive TD learning by defining a different environmental structure and learning objective. We

start by considering arbitrary states  $(s_t)$ , which transition at each time step following a Markov process,

and at each time step the agent samples a random reward from a probability distribution  $r_t \sim R(s_t)$ .

763 The learning objective is now the value of a given state  $V(s_t)$  defined as the *expected cumulative sum of* 

764 *all future rewards* starting from state *s*. Rewards are discounted by a constant discounting factor ( $\gamma$ , with

765  $0 \le \gamma \le 1$ ) each time step. The expectation is taken over stochastic state transitions and sampled rewards:

766 
$$V(s_t) \coloneqq \mathbf{E}[r_t + \gamma r_{t+1} + \gamma^2 r_{t+2} + \gamma^3 r_{t+3} \dots | s_t = S\}]$$

767 Where  $s_t$  is the state at time t,  $r_t$  is the reward sampled at time t and  $V(s_t)$  is the value of the state  $s_t$ .

Since the environment and transitions are assumed to follow a Markov process, the equation above can be
rewritten in a recursive manner. This is known as the Bellman equation<sup>11</sup>:

770 
$$V(s_t) \coloneqq \mathbf{E}[r_t + \gamma \cdot V(s_{t+1})|s_t = S]$$

The agent approximates the true value  $V(s_t)$  with a learned estimate  $\hat{V}(s_t)$ . With this approximation,

before learning converges, the estimates for the left- and right-hand sides are not equal. Thus, after sampling a reward  $r_t \sim R(s_t)$  from the environment, the difference between the two terms in the Bellman equation represents the error in value prediction, called the temporal difference reward prediction error (TD RPE,  $\delta$  below),

776 
$$\delta_t = r_t + \gamma \cdot \hat{V}(s_{t+1}) - \hat{V}(s_t)$$

777 With  $\alpha$  as the learning rate, the updates for the value estimates are:

778 
$$\hat{V}(s_t) \leftarrow \hat{V}(s_t) + \alpha \cdot \delta_t$$

With this definition, the TD RPE contains the difference between the estimated value of states evaluated at consecutive time points. If we fix the discounting factor to be  $\gamma = 1$ , then  $\gamma \cdot \hat{V}(s_{t+1}) - \hat{V}(s_t)$  is the

- temporal derivative of the value function. As a result of this property, unexpected increases and decreases
- in value result in positive and negative transient changes in TD RPE, respectively<sup>95</sup>.
- 783 If dopamine responses encode TD RPEs, then cue-evoked responses can be formulated as:

784 
$$\delta_{cue} = \gamma \cdot \hat{V}(s_{cue}) - \hat{V}(s_b)$$

- 785 Where  $\delta_{cue}$  is the TD RPE induced by the cue,  $\hat{V}(s_b)$  is the value prediction at baseline and  $\hat{V}(s_{cue})$  is
- the value prediction elicited by the cue (which reflects the expected value predicted by each trial type). As
- 787 the  $\hat{V}(s_b)$  is the same across all trial types and represents the average value predictions across them, then
- 788  $\delta_{cue}$  is dominated by the expected value of each trial type. This is a useful feature that we used in our
- simulations for the habenula lesion experiment.

#### 790 **1.2. Distributional TD learning**

- 791 In Results, we used a distributional TD learning model to test whether the subtle changes in the
- distribution of asymmetric scaling factors observed after lesions could lead to the observed changes in cueresponses after learning.
- 794 In distributional TD learning, our learning objective is the entire distribution over cumulative discounted
- future rewards, instead of the value defined above<sup>36,37,39</sup>. We will call this the *return distribution*,  $Z(s_t)$ .
- We can thus write an analogue of the Bellman equation, the 'distributional Bellman equation':
- 797  $Z(s_t) \coloneqq R(s_t) + \gamma \cdot Z(s_{t+1})$

798 The target to learn in distributional TD is now  $V_i(s_t)$  that minimizes for the expectile regression loss:

799  $V_i(s_t) \coloneqq \operatorname{argmin}_{v} \mathbb{E} \left[ (Z(s_t) - v)^2 \cdot \left( \tau_i - \mathbf{1}_{(Z(s_t) - v) < 0} \right) \right]$ 

800 Where  $Z(s_t)$  is a random variable, representing the return distribution, and  $1_f$  is the indicator functions

- 801 that is equal to 1 if the condition in the subscript  $\{f \coloneqq (Z(s_t) v) < 0\}$  is met, and 0 otherwise.
- 802 Minimizing the expectile regression loss makes  $V_i(s_t)$  to converge on the  $\tau_i^{th}$  expectile of the return
- 803 distribution<sup>39</sup>.
- 804 The target is learned by taking samples from the estimated return distribution<sup>39</sup>  $\tilde{z}(s_{t+1}) \sim Z(s_{t+1})$  and 805 from the reward distribution  $r_t \sim R(s_t)$ , to compute the TD error:
- 806  $\delta_{i,t} \coloneqq r_t + \gamma \cdot \tilde{z}(s_{t+1}) V_i(s_t)$

807 Note that  $\tilde{z}(s_{t+1})$  is random so the TD error is also random, and  $\delta_{i,t} \neq r_t + \gamma \cdot V_i(s_{t+1}) - V_i(s_t)$ . For

808 more information regarding the sampling method employed in the simulations see Methods Section 3.3.

809 In addition, the updates are performed with different learning rates  $(\alpha_i^+, \alpha_i^-)$  for positive and negative  $\delta_i$ .

810 This asymmetry in the weighting of the errors used to update  $V_i(s_t)$  is essential to minimize the expectile

811 regression loss.

812 
$$\hat{\delta}_{i,t} = \alpha_i^+ \cdot \delta_{i,t} \dots \text{ if } \delta_{i,t} > 0$$

813 
$$\hat{\delta}_{i,t} = \alpha_i^- \cdot \delta_{i,t} \dots \text{ if } \delta_{i,t} < 0$$

814 The reliance on a single sample for  $\tilde{z}(s_{t+1})$  suffers from high variance. Therefore, for performing the

815 updates we average across a set of M updates, each depending on a single sample  $\delta_{i,t}$ .

816 
$$\mathbf{E}[\Delta V_i(s_t)] = \frac{1}{M} \sum_{j}^{M} \alpha_i^{-} \cdot \delta_{i,j} \cdot \mathbf{1}_{\delta_{i,j} < 0} + \alpha_i^{+} \cdot \delta_{i,j} \cdot \mathbf{1}_{\delta_{i,j} > 0}$$

817 
$$V_i(s_t) \leftarrow V_i(s_t) + \mathbf{E}[\Delta V_i(s_t)]$$

818 This learning rule will asymptotically converge to the  $\tau_i$ -th expectile of the return distribution<sup>39</sup>.

#### 819 **1.3. TD learning with D1 and D2 populations**

It is straightforward to extend the TD learning algorithm to have separate populations for D1 and D2 SPNs<sup>32</sup>. We employed this model to derive dopamine cue responses with Model 1 (Fig. 6i). In this model, the same computation of TD RPE of standard TD learning is still used. Yet, this model differs in the updates and computation of  $\hat{V}(s_t)$ .

As mentioned previously, the updates in the  $P_i$  and  $N_i$  populations happen exclusively with positive or negative TD RPEs, respectively:

826 
$$P(s_t) \leftarrow P(s_t) + \alpha^+ \cdot |\delta_t| - \beta \cdot P(s_t) \dots \text{ if } \delta_t > 0$$

827 
$$N(s_t) \leftarrow N(s_t) + \alpha^- \cdot |\delta_t| - \beta \cdot N(s_t) \dots \text{ if } \delta_t < 0$$

828 Where  $\alpha^+$  and  $\alpha^-$  are the learning rates for the *P* and *N* populations, that we postulate is modulated by 829 baseline dopamine levels. The variable  $\beta \in (0,1)$  is the decay factor, which we keep constant throughout 830 the simulations and serves to stabilize  $P(s_t)$ ,  $N(s_t)$ .

831 The computation of value estimate  $\hat{V}(s_t)$  is given by:

$$\hat{V}(s_t) = P(s_t) - N(s_t)$$

#### 833 1.3.1. Convergence of risk sensitive TD learning

834 We now discuss the convergence of the proposed TD learning algorithm with D1 and D2 populations.

835 This analysis builds on the work in risk-sensitive reinforcement learning  $^{40}$  and the already established

836 results of convergence for stochastic iterative algorithms (e.g., TD learning) (Bertsekas & Tsitsiklis,

837 1996<sup>96</sup>, Proposition 4.4, p. 156).

838 **Theorem**: The results by Bertsekas & Tsitsiklis (1996)<sup>96</sup> establish that, given a sequence  $r_t \in$ 

839  $\mathbb{R}^m$  generated by the iterative algorithm:

840 
$$a_{n+1}(s) = (1 - \sigma_n(s))a_n(s) + \sigma_n(s)((Ha_n)(s) + \omega_n(s)) \quad \forall s \in 1, ..., m \text{ Eq. I}$$

841 The variable  $a_n$  converges to the unique solution  $a^*$  of the equation:  $Ha^* = a^*$  with probability = 1,

842 assuming the following conditions are fulfilled:

#### 843 1. The step sizes $\sigma_i(i)$ are non-negative and satisfy:

844 
$$\sum_{n=0}^{\infty} \sigma_n(s) = \infty \ \forall \ s \in 1, \dots, m$$

845 
$$\sum_{n=0}^{\infty} \sigma_n(s)^2 < \infty \ \forall \ s \in 1, \dots, m$$

846 2. The noise term  $\omega_n(s)$  satisfies:

847 -  $E[\omega_n(s)|\mathcal{F}_n] = 0 \forall s, n$ , where  $\mathcal{F}_n$  denotes the history of the process up to and including time 848 step *n* 

849 - Given any norm  $\|\cdot\|$  on  $\mathbb{R}^m$  there exist constants A and B such that:  $\mathbb{E}[\omega_n^2(s)|\mathcal{F}_n] \le A + B\|r_n\|^2 \quad \forall s, n$ 

851 3. The mapping H is a *maximum norm contraction* (see below for definition)

To prove convergence, we will first discuss the case of risk-sensitive TD learning following <sup>40</sup> and then

discuss TD learning with D1 and D2 populations.

854 We define the risk sensitive TD-learning rule as:

855 
$$\hat{V}_n(s) \leftarrow \hat{V}_{n-1}(s) + \sigma \cdot \mathcal{X}^{\tau}(\delta_{s_{n-1},s_n})$$

856	Where:	
857	-	$\delta_{s_{n-1},s_n} = r_{n-1,n} + \gamma \cdot \hat{V}_{n-1}(s_n) - \hat{V}_n(s_{n-1})$
858	-	The step index is $n \in 0,, \infty$
859	-	The step size $\sigma$ is kept constant across iterations.
860	-	For simplicity in calculations we follow <sup>40</sup> and make use of the operator $\mathcal{X}^K$ with $K \in (-1,1)$
861		$\mathcal{X}^K(x) = (1-K) \cdot x$ if $x > 0$
862		$\mathcal{X}^{K}(x) = (1+K) \cdot x  \dots \text{ if } x \leq 0$
863		It is simple to show that the asymmetric scaling factor used in this paper is a scaled version of
864		the operator. That is: $\tau = 0.5(1 - K)$ and $1 - \tau = 0.5(1 + K)$ .
865	-	In addition, as in <sup>40</sup> , given that the function $X^{\tau}(x)$ is piece-wise differentiable we can apply
866		the mean value theorem to show that for each pair of numbers $(a, b)$ there exists a $\mathcal{E}_{a,b,K} \in$
867		$[1 -  K , 1 +  K ]$ , such that: $\mathcal{E}_{a,b,K} = \frac{\chi^{\tau}(a) - \chi^{\tau}(b)}{a - b}$ . This relationship will become useful in
868		the future.

869 We will re-format the update rule to better match the iterative algorithm above:

870 Adding and subtracting  $\sigma \cdot \hat{V}_{n-1}(s)/\alpha$ 

871 
$$\hat{V}_n(s) \leftarrow (1 - \sigma/\alpha)\hat{V}_{n-1}(s) + \sigma/\alpha \left(\alpha \cdot \mathcal{X}^{\tau}(\delta_{n-1}) + \hat{V}_{n-1}(s)\right)$$

872 Defining an operator that will become useful:

873 
$$\mathcal{T}_{\alpha K}[V](s) \coloneqq V(s) + \alpha \cdot \sum_{i,j \in S} p_{ij} \cdot \mathcal{X}^{K} \cdot \delta_{ij}$$

874 Defining the noise term as:

875 
$$\omega_{n-1}(s) = \hat{V}_{n-1}(s) + \alpha \cdot \mathcal{X}^{K}(\delta_{s_{n-1},s_n}) - \mathcal{T}_{\alpha K}[\hat{V}_{n-1}](s)$$

876 Then our update rule above becomes:

877 
$$\hat{V}_n(s) \leftarrow (1 - \sigma/\alpha)\hat{V}_{n-1}(s) + \sigma/\alpha \left(\mathcal{T}_{\alpha K}[\hat{V}_{n-1}](s) + \omega_{n-1}(s)\right)$$

878 The formulation above can be directly compared to the one of stochastic iterative algorithm theorem

 $\ensuremath{\left(\text{Eq.I}\right)}$  , and now we can check whether the conditions for convergence are met.

880 1. The conditions for the learning rate, are a direct consequence of our choice of the parameter 881 which is a constant in our model and  $0 < \alpha < 1$ .

- 882 2. It has been shown that showed that the conditions for the noise term  $\omega_{n-1}(s)$  as formulated 883 above are satisfied<sup>40</sup>.
- 884 3. Finally, the operator  $\mathcal{T}_{\alpha\tau}[V](s)$  is a contraction mapping as also shown in Bersekas (1996)<sup>40</sup>.

885 Therefore, the variable  $V_n$  converges to the unique solution  $V^*$  for which:

886 
$$V^* = \mathcal{T}_{\alpha K}[V^*] = V^* + \alpha \cdot \sum_{i,j \in S} p_{ij} \cdot \mathcal{X}^K \cdot \delta_{ij}$$

887 We elaborate now on the proof for the contraction mapping of the operator  $\mathcal{T}_{\alpha\tau}[V](s)$ , as this will be 888 useful for the proof of the D1 D2 TD learning model.

**Definition of contraction mapping.** Let (X, d) be a metric space (a set X, with a notion of distance, d,

between points). A mapping  $\mathcal{T}: X \to X$  is a contraction mapping if there exists a constant  $c: 0 \ge c > 1$ such that for all  $x \in X$ :

892 
$$d(\mathcal{T}[x_i], \mathcal{T}[x_i]) \le cd(x_i, x_i)$$

893 That is, a contraction mapping maps points closer together.

Elaborating now on the operator  $\mathcal{T}_{\alpha\tau}[V](s)$  and using  $|\cdot|$  as our distance metric:

895 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)|$$

896 
$$= \left| V_1(i) + \alpha \cdot \sum_{i,j \in S} p_{ij} \cdot \mathcal{X}^K \cdot \left( r_{i,j} + \gamma \, V_1(j) - V_1(i) \right) - V_2(i) + \alpha \right|$$

897 
$$\cdot \sum_{i,j\in S} p_{ij} \cdot \mathcal{X}^{K} \cdot \left( r_{i,j} + \gamma V_{2}(j) - V_{2}(i) \right)$$

898 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)|$$

899 = 
$$V_1(i) - V_2(i)$$

900 
$$+ \alpha \sum_{i,j \in S} p_{ij} \cdot \left( \mathcal{X}^{\tau} \cdot \left( r_{i,j} + \gamma V_1(j) - V_1(i) \right) - \mathcal{X}^{\tau} \cdot \left( r_{i,j} + \gamma V_2(j) - V_2(i) \right) \right) \right|$$

901 Using the relation defined above  $\mathcal{E}_{a,b,K} \cdot (a-b) = \mathcal{X}^{K}(a) - \mathcal{X}^{K}(b)$ 

902 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)|$$

903 
$$= \left| V_1(i) - V_2(i) + \alpha \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1, V_2, K} \cdot \left( \gamma \left( V_1(j) - V_2(i) \right) - \left( V_1(j) - V_2(i) \right) \right) \right|$$

904 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)|$$
905 
$$= \left| \left( 1 - \alpha \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1,V_2,K} \right) \cdot \left( V_1(j) - V_2(i) \right) \right|$$

906 
$$+ \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1,V_2,K} \cdot \left( \gamma \left( V_1(j) - V_2(i) \right) \right)$$

907

908 Given that  $\mathcal{E}_{a,b,K} \in [1 - |K|, 1 + |K|]$  and assuming  $\alpha \in (0, (1 + |K|)^{-1})$ :

909 
$$1 - \alpha \cdot \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1, V_2, K} > 0$$

910 Taking this term outside the  $|\cdot|$  and rearranging:

911 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)| = \left(1 - \alpha \cdot (1 - \gamma) \cdot \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1, V_2, K}\right) | (V_1(j) - V_2(i))|$$

912 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)| = c \cdot |(V_1(j) - V_2(i))|$$

913 Where the term:

914 
$$c = \left(1 - \alpha \cdot (1 - \gamma) \cdot \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1, V_2, K}\right)$$

915 To get the upper boundary of *c* we use the minimum value for the sum, where  $\mathcal{E}_{V_1V_2K} = 1 - |K| \quad \forall i, j \in \mathbb{C}$ 

916 S. And use the assumption that  $\alpha \in (0, (1 + |K|)^{-1})$ :

917 
$$c \le (1 - \alpha \cdot (1 - \gamma) \cdot (1 - |K|))$$

918 
$$\lim_{\alpha \to 0} c = (1 - \alpha \cdot (1 - \gamma) \cdot (1 - |K|) = 1$$

919 To get the lower boundary of *c* we use the maximum value for the sum, where  $\mathcal{E}_{V_1V_2K} = 1 + |K| \quad \forall i, j \in \mathbb{R}$ 

920 S. And use the assumption that  $\alpha \in (0, (1 + |K|)^{-1})$ :

921 
$$c \ge (1 - \alpha \cdot (1 - \gamma) \cdot (1 + |K|))$$

922 
$$\lim_{\alpha \to (1+|K|)^{-1}} c = (1 - (1 + |K|)^{-1} \cdot (1 - \gamma) \cdot (1 + |K|) = \gamma$$

923 Therefore:  $\gamma < c < 1$ 

924 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)| \le c \cdot \left| \left( V_1(j) - V_2(i) \right) \right|$$

925 And the operator  $\mathcal{T}_{\alpha\tau}[V](s)$  is a contraction mapping, under the condition  $\alpha \in (0, (1 + |K|)^{-1})$ 

#### 926 1.3.2. Convergence of TD learning with D1 and D2 populations

927 We define the D1-D2 TD-learning rule as:

928 
$$\hat{V}_n(s) \leftarrow \hat{V}_{n-1}(s) + \alpha \cdot \mathcal{X}^{\tau} \left( \delta_{s_{n-1}, s_n} \right) - \beta \hat{V}_{n-1}(s)$$

929 Note this update rule is analogous to the risk sensitive TD learning rule except for the last term that

930 emerges from the decay factor in the *P*, *N* populations of our model.

931 Performing the same re-arrangement as above we reach:

932 
$$\hat{V}_n(s) \leftarrow (1 - \sigma/\alpha)\hat{V}_{n-1}(s) + \sigma/\alpha \left(\alpha \cdot \mathcal{X}^{\tau}(\delta_{n-1}) + \hat{V}_{n-1}(s) - \alpha \cdot \beta \hat{V}_{n-1}(s)\right)$$

933 We define a new operator  $\mathcal{T}'_{\alpha K}[V](s)$ :

934 
$$\mathcal{T'}_{\alpha K}[V](s) \coloneqq (1 - \alpha \cdot \beta) \cdot V(s) + \alpha \cdot \sum_{i,j \in S} p_{ij} \cdot \mathcal{X}^K \cdot \delta_{ij}$$
935 And the noise then is defined as:

936 
$$\omega_{n-1}(s) = \alpha \cdot \mathcal{X}^{K} \left( \delta_{s_{n-1}, s_n} \right) + \hat{V}_{n-1}(s) - \alpha \cdot \beta \cdot \hat{V}_{n-1}(s) - \mathcal{T}'_{\alpha K} \left[ \hat{V}_{n-1} \right](s)$$

937 The update becomes:

938 
$$\hat{V}_n(s) \leftarrow (1 - \sigma/\alpha)\hat{V}_{n-1}(s) + \sigma/\alpha \left(\mathcal{T}'_{\alpha K} [\hat{V}_{n-1}](s) + \omega_{n-1}(s)\right)$$

939 The noise term reduces to the same expression as the one of TD learning, and so it fullfils the

940 requirements for the theorem of stochastic iterative algorithms. We will now test whether the operator

941  $\mathcal{T}'_{\alpha K}[V](s)$  also represents a contraction map.

942 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)|$$
  
943  $= \left| V_1(i) + \alpha \cdot \sum_{i,j \in S} p_{ij} \cdot \mathcal{X}^K \cdot (r_{i,j} + \gamma V_1(j) - V_1(i)) - \alpha \cdot \beta \cdot V_1(i) + V_2(i) + \alpha \right|$ 

944 
$$\cdot \sum_{i,j\in S} p_{ij} \cdot \mathcal{X}^{K} \cdot \left( r_{i,j} + \gamma V_{2}(j) - V_{2}(i) \right) - \alpha \cdot \beta \cdot V_{2}(i) \right|$$

945 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)|$$
  
946  $= \left| V_1(i) - V_2(i) - \alpha \cdot \beta(V_1(i) - V_2(i)) \right|$ 

947 
$$+ \alpha \sum_{i,j \in S} p_{ij} \cdot \left( \mathcal{X}^{\tau} \cdot \left( r_{i,j} + \gamma V_1(j) - V_1(i) \right) - \mathcal{X}^{\tau} \cdot \left( r_{i,j} + \gamma V_2(j) - V_2(i) \right) \right)$$

948 Using the relation defined above  $\mathcal{E}_{a,b,K} \cdot (a-b) = \mathcal{X}^K(a) - \mathcal{X}^K(b)$ 

949 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)|$$

950 
$$= \left| (1 - \alpha \beta) \cdot (V_1(i) - V_2(i)) \right|$$

951 
$$+ \alpha \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1, V_2, K} \cdot \left( \gamma \left( V_1(j) - V_2(i) \right) - \left( V_1(j) - V_2(i) \right) \right) \right|$$

952 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)|$$

953 
$$= \left| \left( 1 - \alpha \cdot \beta - \alpha \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1,V_2,K} + \gamma \alpha \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1,V_2,K} \right) \cdot \left( V_1(j) - V_2(i) \right) \right|$$

954 
$$|\mathcal{T}_{\alpha K}[V_1](i) - \mathcal{T}_{\alpha K}[V_2](i)| = c \cdot |(V_1(j) - V_2(i))|$$

955 Where the term:

968

956 
$$c = \left(1 - \alpha \cdot \beta - \alpha \cdot (1 - \gamma) \cdot \sum_{i,j \in S} p_{ij} \cdot \mathcal{E}_{V_1, V_2, K}\right)$$

957 To get the upper boundary of *c* we use the minimum value for the sum, where  $\mathcal{E}_{V_1V_2K} = 1 - |K| \quad \forall i, j \in$ 958 *S*, and use the assumption that  $\alpha \in (0, (1 + |K|)^{-1})$ :

959  $c \le 1 - \alpha \cdot \beta - \alpha \cdot (1 - \gamma) \cdot (1 - |K|)$ 

960 
$$\lim_{\alpha \to 0} c = 1 - \alpha \cdot \beta - \alpha \cdot (1 - \gamma) \cdot (1 - |K|) = 1$$

961 To get the lower boundary of *c* we use the maximum value for the sum, where  $\mathcal{E}_{V_1V_2K} = 1 + |K| \quad \forall i, j \in$ 962 *S*, and use the assumption that  $\alpha \in (0, (1 + |K|)^{-1})$ :

963  $c \ge (1 - \alpha \cdot \beta - \alpha \cdot (1 - \gamma) \cdot (1 + |K|))$ 

964 
$$\lim_{\alpha \to (1+|K|)^{-1}} c = (1 - (1+|K|)^{-1} \cdot \beta - (1+|K|)^{-1} \cdot (1-\gamma) \cdot (1+|K|) = \gamma - (1+|K|)^{-1} \cdot \beta$$

965 Given that we want  $c \ge 0$  we can find the parameter ranges to achieve this:

966 
$$c = \gamma - (1 + |K|)^{-1} \cdot \beta \ge 0$$

967 Given that:  $K \in (-1,1)$ , we use the minimum value of |K| = 0 to find the limit of c:

$$\lim_{|K|\to 0} c = \gamma - \beta$$

969 So the condition  $\gamma \ge \beta$  needs to be present to keep:  $0 \le c < 1$ .

970 Under these conditions, the operator  $\mathcal{T}'_{\alpha K}[V](s)$  also represents a contraction map.

971 
$$|\mathcal{T}'_{\alpha K}[V_1](i) - \mathcal{T}'_{\alpha K}[V_2](i)| \le c \cdot \left| \left( V_1(j) - V_2(i) \right) \right|$$

972 Stochastic fixed point for the value estimate:

Having shown convergence of the algorithm, we will now derive the convergent points for our algorithm
using stochastic fixed points. For clarity, we estimate the stochastic fixed point dropping the dependency
on time.

976 If learning between *P* and *N* is symmetric  $\alpha^+ = \alpha^- = \alpha$ . We derive the convergent estimate of  $V(s_t)$ 977 with a fixed-point approach. First, we subtract the *P* and *N* update equations, to arrive to the update in

978 the  $\hat{V}(s_t)$  between the (n) and the (n + 1) update:

979 
$$\hat{V}^{(n+1)}(s_i) \leftarrow \hat{V}^{(n)}(s_i) + \alpha \cdot \delta^{(n)} - \beta \cdot \hat{V}^{(n)}(s_i)$$

980 Where the superscripts indicate the iteration number. We can now derive the stochastic fixed-point 981 for  $\hat{V}(s_t)$ :

982 
$$\mathbf{E}[\hat{V}^{(n+1)}(s_i) - \hat{V}^{(n)}(s_i)] = 0$$

983 
$$\mathbf{E}[\alpha \cdot \delta^{(n)} - \beta \cdot \hat{V}^{(n)}(s_i)] = 0$$

984 
$$\mathbf{E}\left[\alpha \cdot \left(r^{(n)} - \hat{V}(s_i)\right) - \beta \cdot \hat{V}^{(n)}(s_i)\right] = 0$$

985 
$$\alpha \cdot \mathbf{E}[r] - (\alpha + \beta) \cdot \mathbf{E}[\hat{V}(s_i)] = 0$$

986 
$$\mathbf{E}[\hat{V}(s_i)] = \frac{\alpha}{\alpha + \beta} \mathbf{E}[r]$$

987 
$$\boldsymbol{V}^* = \frac{\alpha}{\alpha + \beta} \mathbf{E}[r]$$

988 Where  $V^* = \mathbf{E}[\hat{V}(s_i)]$  is the value around which  $\hat{V}(s_i)$  is expected to fluctuate after convergence.

989 Throughout this study, we have manipulated the learning rates between *P* and *N* to be asymmetric  $\alpha^+ \neq$ 990  $\alpha^-$  or, equivalently,  $\tau \neq 1 - \tau$ . We can find the stochastic fixed point for this more general case:

991 
$$\mathbf{E}[\hat{V}^{(n+1)}(s_i) - \hat{V}^{(n)}(s_i)] = 0$$

992 
$$\mathbf{E}[\tau \cdot |\delta^{(n)}| \cdot \mathbf{1}_{\delta > \mathbf{0}} - (1 - \tau) \cdot |\delta^{(n)}| \cdot \mathbf{1}_{\delta < \mathbf{0}} - \beta \cdot \hat{\mathcal{V}}^{(n)}(s_i)] = 0$$

993 To take the expectation we use the definition:  $E[X] = \sum_{i} p(x_i) \cdot x_i$ . For a Bernoulli distribution,  $p(x_i)$ 994 takes two values:

- 995  $p(x_i) = p$  if reward is delivered and, thus r = 1,  $\delta_t > 0$ ,
- 996  $p(x_i) = (1-p)$  if reward is not delivered and, thus r = 0,  $\delta_t < 0$ ,

997 Therefore, we can resolve the expectation and expand the RPEs:

998 
$$\mathbf{E}[\tau \cdot |\delta^{(n)}| \cdot \mathbf{1}_{\delta > 0} - (1 - \tau) \cdot |\delta^{(n)}| \cdot \mathbf{1}_{\delta < 0} - \beta \cdot \hat{\mathcal{V}}^{(n)}(s_i)] = 0$$

999 
$$\tau \cdot \mathbf{E}[|r - \hat{V}(s_i)| \cdot \mathbf{1}_{\delta > 0}] - (1 - \tau) \cdot \mathbf{E}[|-\hat{V}(s_i)| \cdot \mathbf{1}_{\delta < 0}] - \beta \cdot \mathbf{E}[\hat{V}(s_i)] = 0$$

1000 Taking the absolute values:

1001 
$$|r - \hat{V}(s_i)| = r - \hat{V}(s_i) \dots \text{ if } (r - \hat{V}(s_i)) > 0$$

1002 
$$|-\hat{V}(s_i)| = \hat{V}(s_i) \dots \text{ if } (-\hat{V}(s_i)) < 0$$

1003 
$$\tau \cdot \mathbf{E}\left[\left(r - \hat{V}(s_i)\right) \cdot \mathbf{1}_{\delta > 0}\right] - (1 - \tau) \cdot \mathbf{E}\left[\hat{V}(s_i) \cdot \mathbf{1}_{\delta < 0}\right] - \beta \cdot \mathbf{E}\left[\hat{V}(s_i)\right] = 0$$

1004 Replacing stochastic fixed point:  $\mathbf{E}[\hat{V}(s_t)] = V^*$  and taking the expectations:

1005 
$$\beta \cdot V^* = \tau \cdot p \cdot (r - V^*) - (1 - \tau) \cdot (1 - p) \cdot V^*$$

1006 Rearranging and isolating  $V^*$ , we obtain:

1007 
$$V^* = \frac{\frac{\tau}{1-\tau} \cdot \frac{p}{1-p} \cdot r}{\frac{\tau}{1-\tau} \cdot \frac{p}{1-p} + 1 + \frac{\beta}{(1-\tau) \cdot (1-p)}}$$

## 1008 Stochastic fixed point for P and N populations:

1009 We have mentioned that the decay term ( $\beta$ ) in the update equations serves to stabilize the estimates of the 1010 *P* and *N* populations (i.e., avoid infinite increases). We can observe the influence of  $\beta$  by computing the 1011 stochastic fixed points for these variables.

1012 For the *P* population:

1013 
$$\mathbf{E}[P^{(n+1)}(s_t) - P^{(n)}(s_t)] = 0$$

1014 
$$\mathbf{E}[\tau \cdot | \mathbf{r} - V^{(n)}(s_t) | \cdot \mathbf{1}_{\delta > \mathbf{0}} - \beta \cdot P^{(n)}(s_t)] = \mathbf{0}$$

1015  $p \cdot \tau \cdot (r - V^*) - \beta \cdot P^* = 0$ 

1016 
$$P^* = \frac{p \cdot \tau}{\beta} \cdot (r - V^*)$$

1017 Similarly, for the *N* population:

1018 
$$\mathbf{E}[N^{(n+1)}(s_t) - N^{(n)}(s_t)] = 0$$

1019 
$$\mathbf{E}[(1-\tau) \cdot \left| -V^{(n)} \right| \cdot \mathbf{1}_{\delta < \mathbf{0}} - \beta \cdot N^{(n)}(s_t)] = 0$$

1020 
$$(1-p) \cdot (1-\tau) \cdot V^* - \beta \cdot N^* = 0$$

1021 
$$N^* = \frac{(1-p)\cdot(1-\tau)}{\beta} \cdot V^*$$

1022 As it can be seen in the stochastic fixed points  $P^*$ ,  $N^*$ , the term  $\frac{1}{\beta}$  is a proportionality constant. Therefore:

1023 
$$\lim_{\beta \to 0} P^* = \lim_{\beta \to 0} \left( \frac{p \cdot \tau}{\beta} \cdot (r - V^*) \right) = \text{undefined}$$

1024 
$$\lim_{\beta \to 0} N^* = \lim_{\beta \to 0} \left( \frac{(1-p) \cdot (1-\tau)}{\beta} \cdot V^* \right) = \text{undefined}$$

1025 So,  $\beta \neq 0$  needs to be met for the stochastic fixed points  $P^*$ ,  $N^*$  to exist. In Extended Data Fig. 1 we show 1026 empirically that the convergence rate is slower as  $\beta$  gets closer to 0, but it is always achieved.

#### 1027 1.3.3. Sensitivity of learned variables in D1-D2 model to parameters

1028 The conditions for the D1-D2 model to reproduce the data from our habenula lesion experiment and some1029 of the previous studies are that:

- 10301. The bias in  $V^*$  induced by the asymmetric learning rates doesn't change the monotonicity of the1031learned values as a function of the true expected value of the return distribution  $\mathbf{E}[R(s)]$ . In other1032words, regardless of the level of 'optimism' or 'pessimism',  $V^*$  monotonically increases with1033 $\mathbf{E}[R(s)]$ .
- 10342. Asymmetric learning rates change the concavity of  $V^*$  as a function of  $\mathbf{E}[R(s)]$ : 'Optimistic' or1035'pessimistic' value functions are concave or convex with respect to  $\mathbf{E}[R(s)]$ , respectively.
- 1036

1037 We will now analyze whether these conditions are met, considering the range of parameters of relevance: 1038  $0 < \tau < 1, r \neq 0$  and  $0 < \beta < 1$ 

1039 For the condition 1 to be met, the first derivative of  $V^*$  with respect to  $\mathbf{E}[R(s)]$  should always be positive.

1040 In the case of Bernoulli return distributions, the derivative of  $V^*$  with respect to p(reward) is

1041 
$$\frac{\partial V^*}{\partial p} = \frac{\partial}{\partial p} \left( \frac{\frac{\tau}{1-\tau} \cdot \frac{p}{1-p} \cdot r}{\frac{\tau}{1-\tau} \cdot \frac{p}{1-p} + 1 + \frac{\beta}{(1-\tau) \cdot (1-p)}} \right) = \frac{\tau \cdot r \cdot (\tau-\beta-1)}{(\tau \cdot (2p-1) + \beta - \tau + 1)^2}$$

1042 We can look at the fixed points of this expression, as they correspond to the value of *p* at which the

1043 derivative changes the sign. This expression has fixed points at:  $\tau = 0$ , r = 0, and  $\beta = \tau - 1$ . Given our 1044 parameters' ranges:  $0 < \tau < 1$ ,  $r \neq 0$  and  $0 < \beta < 1$ , none of those fixed points are present within those

1045 ranges. In addition, it can be seen that this  $\left(\frac{\partial V^*}{\partial p}\right)$  is positive for the parameter values within those ranges.

1046 Therefore, knowing that the derivative won't reach any fixed point,  $V^*$  is always a growing monotonic 1047 function with respect to p.

For the condition 2 to be met, we can analyze the second derivative of  $V^*$  with respect to  $\mathbf{E}[R(s)]$  as it indicates the convexity of a function. The conditions to be mat are:

1050 - 
$$V^*$$
 is convex if it is 'pessimistic': if  $\tau < 0.5 \rightarrow \frac{\partial^2 V}{\partial p^2} > 0$ 

1051 - 
$$V^*$$
 is concave if it is 'optimistic: if  $\tau > 0.5 \rightarrow \frac{\partial^2 V}{\partial p^2} < 0$ 

1052 In the case of Bernoulli return distributions, we take the second derivative of  $V^*$  with respect to 1053 p(reward):

1054 
$$\frac{\partial^2 V^*}{\partial p^2} = \frac{\partial^2}{\partial p^2} \left( \frac{\frac{\tau}{1-\tau} \cdot \frac{p}{1-p} \cdot r}{\frac{\tau}{1-\tau} \cdot \frac{p}{1-p} + 1 + \frac{\beta}{(1-\tau) \cdot (1-p)}} \right) = \frac{2\tau \cdot (2\tau-1) \cdot r \cdot (\tau-\beta-1)}{(\tau \cdot (2p-1) + \beta - p + 1)^3}$$

We can again look at the fixed points of this expression. These happen at:  $\tau = 0$ , r = 0, and  $\beta = \tau - 1$ and  $\tau = 0.5$ . Among them, the only fixed point within our parameters range is the latter. In addition, by replacing  $\tau$  in the expression above, it is easily shown that it is positive if  $\tau < 0.5$  and negative if  $\tau > 0.5$ . Thus, given that the ranges for the parameters are such that the second derivative won't reach any other fixed point, condition 2 will always be met.

### 1060 **1.4. Distributional TD learning with D1 and D2 populations**

1061 The signatures of distributional RL were preserved in dopamine neurons firing rates after habenula

- 1062 lesions (Extended Data Fig. 3-4). Therefore, we considered a third alternative to model 1 and 2, that
- assigns different functions to each of the mechanisms for asymmetric learning rates.

1064 In this model (Extended Data Fig. 13) the single cell asymmetric scaling factors  $(\alpha_i^+, \alpha_i^-)$  give rise to a

1065 distributional expectile code for value and are implemented at the level of the scaling of RPE-evoked

1066 responses of dopamine neurons:

1067 
$$\delta_{i,t} \coloneqq r_t + \gamma \cdot \tilde{z}(s_{t+1}) - V_i(s_t)$$

1068 
$$\hat{\delta}_{i,t} = \alpha_i^+ \cdot \delta_{i,t} \dots \text{ if } \delta_{i,t} > 0$$

1069 
$$\hat{\delta}_{i,t} = \alpha_i^- \cdot \delta_{i,t} \dots \text{ if } \delta_{i,t} < 0$$

1070

1071 The modulation of receptor sensitivities, carried out downstream at the SPN level, gives rise to the global 1072 rescaling of the value updates  $(\eta^+, \eta^-)$  (Extended Data Fig. 13A):

1073 
$$P_i(s_t) \leftarrow P_i(s_t) + \eta^+ \cdot \left| \hat{\delta}_i(t) \right| - \beta \cdot P_i(s_t) \dots \text{ if } \delta_i(t) > 0$$

1074 
$$N_i(s_t) \leftarrow N_i(s_t) + \eta^- \cdot \left|\hat{\delta}_{i,j}(t)\right| - \beta \cdot N_i(s_t) \dots \text{ if } \delta_i(t) > 0$$

1075 
$$\widehat{V}_i(s_t) = P_i(s_t) - N_i(s_t)$$

1076 These set of update equations are equivalent to a modified version of the update equation of distributional1077 RL:

1078 
$$[\Delta V_i(s_t)] = \frac{1}{N} \sum_{j=1}^{N} \eta^+ \cdot \alpha_i^+ \cdot \delta_{i,j} \cdot I_{\delta_{i,j}>0} + \eta^- \cdot \alpha_i^- \cdot \delta_{i,j} \cdot I_{\delta_{i,j}>0}$$

1079 
$$V_i(s_t) \leftarrow V_i(s_t) + \mathbf{E}[\Delta V_i(s_t)]$$

Thus, this model can give rise to biases in value learning (Extended Data Fig. 13), while keeping intact information about the value distribution. By employing the results from the biophysical model (Fig. 6), we found that this distributional TD model can parsimoniously explain all aspects of the data in the habenula lesion study (Extended Data Fig. 12B), including the features of a distributional code and the optimistic biases observed in behavior and dopamine cue-evoked responses (Extended Data Fig. 12).

## 1085 **1.5. Dependency of model on assumption: Log vs. linear scaling of receptor occupancy curves**

1086 Through this work, we have used the dose-occupancy curves of D1 and D2 receptors to derive the

1087 receptor sensitivities that result in the asymmetric scaling factors in Model 1. It is important to note that

1088 the slopes of the receptor occupancy curve (= receptor sensitivity) were obtained from the receptor

1089 occupancy curves plotted as a function of log of dopamine concentrations.

1090 
$$\alpha^{+} = \frac{\Delta \text{Occ}_{\text{D1}}}{\Delta \log(\text{C}_{DA^{+}})}$$

1091 
$$\alpha^{-} = \frac{\Delta Occ_{D2}}{\Delta \log(C_{DA^{-}})}$$

1092

1093 To show that this assumption is not essential, we now derive the receptors sensitivities assuming linear 1094 changes in dopamine levels due to RPE-evoked responses.

1095 
$$\alpha^+ = \frac{\Delta \text{Occ}_{\text{D1}}}{\Delta \text{C}_{DA^+}}$$

1096 
$$\alpha^- = \frac{\Delta Occ_{D2}}{\Delta}$$

1097 As shown in Extended Data Fig. 9, the choice of a linear versus log scale affects the absolute magnitude

1098 of the derived receptor sensitivities, but the normalized metric  $\tau = \frac{\alpha^+}{\alpha^- + \alpha^+}$  holds the same relationship to

1099 baseline dopamine levels with a small shift in the curve (Extended Data Fig.9, right panel). The

1100 normalized metric is the factor determining the update asymmetries and, thus, the stochastic fixed points

1101 at which the variables converge.

## 1102 1.6. Normative motivation for two-factor learning rule

- 1103 We have used in the previous models a so-called *two factor learning rule*, where the value updates
- 1104 depend only on the presynaptic activity (i.e., state input) and TD RPEs. Here, we motivate this choice
- 1105 from a normative approach based on previous work<sup>11</sup>.

- 1106 Consider a linear approximation for value, where the value function ( $\hat{V}$ ) is the output of a single linear
- 1107 neuron. Here,  $\hat{V}$  is a linear function of the input feature-vector representing the state  $\mathbf{x}(s) =$
- 1108  $(x_1(s), \dots, x_n(s))$ , parametrized with a weight vector  $\mathbf{w} = (w_1, \dots, w_n)$ .
- 1109  $\hat{V}(s, w) = w^T x(s)$
- 1110 To put it into neural terms, we can think of  $x_i(s)$  as the presynaptic activity onto the value neuron  $\hat{V}$ ,
- 1111 with a synaptic efficacy  $w_i$ .

As before, the agent computes the TD error based on this linear approximation for value and the sampledreward:

1114  $\delta_t = r_t + \gamma \cdot \hat{V}(s_{t+1}, \mathbf{w}) - \hat{V}(s_t, \mathbf{w})$ 

In the problem of *value prediction*, the agent aims to achieve the highest accuracy of prediction. One way to achieve this is to perform *stochastic gradient descent* (SGD) with respect to the parameters (w) of the value function to minimize the objective function such as the squared error  $(\delta_t^2)$ . We can define this optimization problem as:  $\operatorname{argmin}_w \left(\frac{1}{2}\delta^2\right)$  where we have deliberately chosen the constant  $\frac{1}{2}$  for clarity, but it doesn't change the end results.

- 1120 To perform SGD in this minimization problem, the parameters (w) should be updated in the opposite
- 1121 direction of the gradient of the loss with respect to the parameters (i.e., opposite to  $\nabla_w (\frac{1}{2} \delta^2)$ ):

1122 
$$\mathbf{w} \leftarrow \mathbf{w} - \boldsymbol{\alpha} \cdot \nabla_{\mathbf{w}} \left(\frac{1}{2}\delta^2\right)$$

1123 Where  $\alpha$  is the learning rate. To compute the gradient, we use the chain rule:

1124 
$$\nabla_{\mathbf{w}} \left(\frac{1}{2}\delta^{2}\right) = \frac{\partial \left(1/2 \,\delta^{2}\right)}{\partial \,\hat{V}} \cdot \frac{\partial \hat{V}}{\partial \,\mathbf{w}} = \frac{\partial \left(1/2 \,\left(r - \hat{V}\right)^{2}\right)}{\partial \,\hat{V}} \cdot \frac{\partial \mathbf{w}^{T} x(s_{t})}{\partial \,\mathbf{w}} = \frac{-2(r - V)}{2} \cdot x(s_{t}) = -\delta \cdot x(s_{t})$$

- 1125 Therefore, the update for the parameters of the value function is:
- 1126  $\mathbf{w} \leftarrow \mathbf{w} + \boldsymbol{\alpha} \cdot \boldsymbol{\delta} \cdot \boldsymbol{x}(s_t)$

1127 The term  $\delta \cdot \mathbf{x}(s_t)$  in the equation above is what we call a *two-factor learning rule*, dependent only on the 1128 presynaptic activity and not contingent on the post-synaptic activity.

1129 The development of the TD learning model with D1 and D2 populations (section 1.3) has respected this

1130 learning rule, complying with what is required for SGD in the value prediction problem. Note that we

- 1131 have implicitly developed our models with a complete serial compound representation (CSC) of the
- 1132 states<sup>11</sup>, where  $x(s_t) = 1$  in a single element  $x_i(s_t)$  representing the current state and 0 otherwise. It can
- be shown that with this representation, the update equation above is equivalent to:

1134 
$$\hat{V} \leftarrow \hat{V} + \alpha \cdot \delta$$

1135

## 1136 **2.** Computational model of dopamine release and receptor occupancy

- 1137 To predict changes in dopamine concentrations and receptor occupancies (Fig. 6), we employed a
- 1138 biophysical model developed elsehwhere<sup>59</sup>. It presents two interacting dynamical systems. The first
- 1139 system models the change in receptor occupancies while the second the change in dopamine levels per
- 1140 unit time.
- 1141 In the first system, the occupancy of receptors is modelled as a binding reaction between dopamine (*DA*)
- 1142 and D1 or D2 receptors (R), using the constants for forward and backward reactions  $(k_{on}, k_{off})$ .

1143 
$$DA + R_{k_{off}} \rightleftharpoons^{k_{on}} DA: R$$

1144 This formulation results in the following equation for the change in receptor occupancy Occ(t) per unit 1145 time:

1146 
$$\frac{d\operatorname{Occ}(t)}{dt} = (1 - \operatorname{Occ}(t)) \times k_{on} \times C_{DA}(t) - \operatorname{Occ}(t) \times k_{off}$$

- 1147 The values used for the association and dissociation constants for each receptor type ( $k_{on}$  and  $k_{off}$ ,
- 1148 respectively) are detailed in Table 1.
- 1149 In the second system, the change in dopamine concentration ( $C_{DA}(t)$ ) is a function of both dopamine
- release and uptake.

1151 
$$\frac{dC_{DA}(t)}{dt} = DA_{release}(t) - DA_{uptake}(t)$$

1152 Dopamine release is a product of firing rate (v(t)) and release capacity  $(\gamma(t))$ 

1154 
$$DA_{release}(t) = \gamma(t) \cdot \nu(t)$$

1153 Where:

1155 1. v(t) is the firing rate of dopamine neurons, provided by the neural data.

1156 2.  $\gamma(t) = \gamma_{pr_n} \cdot P_r \cdot G_{D2}(t)$  is defined as the increase in  $C_{DA}(t)$  by a single synchronized action 1157 potential:

- 1158 a.  $P_r = 1$  release probability in the absence of presynaptic D2-autorreceptors,
- 1159 b.  $\gamma_{pr_n} = 2$  release capacity in the absence of presynaptic D2-autorreceptors. This value was set 1160 to be deliberately high and anticipates a ~50% reduction by terminal feedback.
- 1161 c.  $G_{D2}(t)$  is a multiplicative gain that represents the modulation of dopamine release by D2-1162 autorreceptors. This is a decaying function of the occupancy of D2-autorreceptors
- 1163  $(Occ_{D2_a}(t))$  which is modelled by the same binding reaction explained above. The gain is
- 1164 parametrized by the autoreceptor efficacy,  $\alpha = 3$ . The smaller the  $\alpha$  the less the decay in 1165 release with receptor occupancy.

1166 
$$G_{D2}(t) = \frac{1}{1 + \alpha \cdot \operatorname{Occ}_{D2a}(t)}$$

1167 Dopamine uptake is a function of the uptake of dopamine by the dopamine transporter (DAT) and other1168 non-DAT sources

1169 
$$DA_{uptake}(t) = dt \cdot \left(\frac{V_{max}^{pr_n} \cdot C_{DA}(t)}{K_m + C_{DA}(t)} - K_{nonDAT}\right)$$

- 1170 Where:
- 1171  $V_{max}^{pr_n} = 1500 \frac{nM}{sec}$ s the maximal uptake capacity assuming approximately 100 terminals in the 1172 near surroundings.

1173 -  $K_m = 160 nM$ , is the Michaelis-Menten parameter for uptake mediated by DAT

- 1174  $K_{nonDAT} = 0.04 \, nM$  is a constant for the dopamine removal not mediated by DAT. For 1175 example, monoamine oxidase (MAO) and noepinephrine transporter (NET) mediated uptake.
- 1176 The variables of the model reported in Fig. 6 correspond to:  $Occ_{D1}(t)$ ,  $Occ_{D2}(t)$ ,  $C_{DA}(t)$ . We used as
- 1177 input to the model the firing rates derived from the electrophysiological recording of optogenetically
- 1178 identified dopamine neurons conducted in Tian and Uchida (2015)<sup>55</sup>. This modeling, while considering
- 1179 major processes, does not take into account all of the complexity of the biological environment in the

1180 brain, yet we used this model to obtain an approximate estimate of the order of changes in dopamine

- 1181 concentrations and receptor occupancies.
- 1182 3. Simulation details of habenula lesion data

#### 1183 **3.1. Biophysical model simulations**

1184 We used the computational model described previously (methods section 2) <sup>59</sup> to calculate the

1185 extracellular dopamine levels and estimate the occupancy of postsynaptic receptors from the habenula

1186 lesion dataset. The model was driven by the average spike rate of dopamine neurons recorded from

1187 control or lesioned animals. For each recorded dopamine neuron, the simulations were carried on a trial

1188 by trial basis that consisted of a time window [-15, 20] sec with respect to cue onset. A relatively large

1189 window was used to allow for the relevant variables to stabilize in its baseline, as the simulations were

1190 initialized at zero.

1191 For each trial, spikes were first binned with 10-ms windows and then smoothed by a Gaussian kernel

- 1192 ( $\sigma = 0.3 \times (ISI_{mean})$ ). All trials were then averaged across trials, to determine the mean single-cell
- 1193 response for dopamine release and D1 and D2 receptor activation. Final average dopamine concentrations
- and receptor occupancies were obtained from the average of all mean single-cell responses.

#### 1195 *Computation of receptors sensitivities from the model results*

1196 We computed the receptor sensitivity from the occupancies  $Occ_{D1}$ ,  $Occ_{D2}$  and their theoretical dose-

1197 occupancy curves. Starting from the occupancy at baseline, we derived the change in occupancy as a

1198 function of the transients in dopamine concentration C<sub>DA</sub> elicited by RPE-evoked dopamine responses, at

1199 the level of the population average.

1200 The ratio between these quantities corresponds to the receptors' sensitives. These are transferred as  $\alpha^+$ 

1201 and  $\alpha^-$  to our reinforcement learning model (model 1):

1202 
$$\alpha^+ = \frac{\Delta O \operatorname{cc}_{D1}}{\Delta C_{DA}} \dots \text{ if } \Delta C_{DA} > 0$$

1203 
$$\alpha^{-} = \frac{\Delta O \operatorname{cc}_{D2}}{\Delta C_{DA}} \dots \text{ if } \Delta C_{DA} < 0$$

1204 Where  $\Delta C_{DA}$ ,  $\Delta Occ_{D1}$ ,  $\Delta Occ_{D2}$  are the changes computed with respect to baseline, as:  $\Delta x =$ 

1205  $\bar{x}_{outcome} - \bar{x}_b$ , for each variable  $x = \{C_{DA}, Occ_{D1}, Occ_{D2}\}$ . Where  $\bar{x}$  denotes the population average

response for each group. The outcome responses were taken as the average from [0,1] sec after outcome onset, while the baseline was taken as the average from [-1, 0] sec with respect to cue onset.

#### 1208 3.2. Model 1 simulations

1209 The simulations for Model 1 were carried out with a TD learning model with D1 and D2 populations

- 1210 (methods section 1.3). We ran the simulations using the resultant receptor sensitivities from the
- 1211 biophysical model as the population-level asymmetric learning rates in Model 1 (i.e., the learning rates
- 1212  $\alpha^+$ ,  $\alpha^-$  for *P* and *N* updates). The simulations were run for 3,000 trials on the Pavlovian conditioning task
- 1213 used in the study<sup>55</sup>. We assumed a uniform distribution of trial types across the session. Each trial
- 1214 consisted of 4 states (baseline, cue, delay, reward), assuming Markovian dynamics between them. All
- 1215 variables were initialized at zero. The model had as hyper-parameters a discounting factor of  $\gamma = 0.99$
- 1216 and a decay term  $\beta = 0.002$ . We report in Fig. 4, Model 1 results assuming a uniform scaling of TD
- 1217 RPEs across the neuronal population. In Extended Data Fig. 12 we show that this model reproduces key
- 1218 signatures of the data irrespective of the choice of the decay factor  $\beta$ .
- 1219 The results are not dependent on a uniform scaling of TD RPEs. Given that distributional RL signatures
- 1220 were preserved in the data even after habenula lesions, we also considered Model 1 under the
- 1221 distributional TD learning framework (Extended Data Fig. 13). For this, we used the distribution of single
- 1222 cell asymmetric scaling factors  $(\alpha_i^+, \alpha_i^-)$  derived from the dopamine neurons firing rates. This model also
- 1223 reproduced key signatures of the data irrespective of the choice of the decay factor  $\beta$  (Extended Data Fig.
- 1224 12).

#### 1225 3.3. Model 2 simulations

- 1226 The simulations for Model 2 were carried out with a TD learning model. As with Model 1, simulations
- 1227 were run for 3,000 trials on the Pavlovian conditioning task<sup>55</sup>. We assumed a uniform distribution of trial
- 1228 types across the session. Each trial consisted of 4 states (baseline, cue, delay, reward), assuming
- 1229 Markovian dynamics between them. All variables were initialized at zero. The model had as parameters a
- 1230 discounting factor of  $\gamma = 0.99$ .
- 1231 We used the distribution of single cell asymmetric scaling factors derived from the firing rates of
- 1232 dopamine neurons as  $\alpha_i^+$ ,  $\alpha_i^-$ . In section 1.2 we emphasized that in order to accurately compute the TD
- 1233 RPE in distributional TD, we require taking samples from the estimated return distribution
- 1234  $\tilde{z}_i(s_{t+1}) \sim Z(s_{t+1})$ . We did this by running an optimization process where we minimize for the expectile

1235 loss between the taken samples  $\tilde{z}_i(s_{t+1})$ ,  $V_i(s_{t+1})$  from the model, and  $\tau_i$  as estimated from the data.

1236 The problem was defined as  $\operatorname{argmin}_{s_i \dots s_m} \mathcal{L}(s, V, \tau)$  where:

1237 
$$\mathcal{L}(s, V, \tau) = \frac{1}{M} \sum_{m=1}^{M} \sum_{i=1}^{N} |\tau_i - \mathbf{I}_{s_m < V_n}| (\hat{z}_m - V_i)^2$$
, for N neurons and M samples

- 1238 In the simulations, we took *M* samples where *M* equals the number of neurons (*N*) and performed an
- 1239 update taking the expectation across all samples as described in the methods section 1.3.

#### 1240 4. Simulations details for replications of previous experimental results

#### 1241 **4.1.** Cools et al. (2009)

- 1242 We simulate the results from Cools et al. (2009) (Fig. 7, Extended Data Fig. 6-7) in which they tested the
- 1243 effects of bromocriptine in altering learning rate asymmetry<sup>24</sup>. In their study, they performed a reversal
- 1244 learning task and reported a parameter called 'relative reversal learning (RRL)', equivalent to the
- 1245 difference between the positive and negative learning rates in our model. We computed this as:  $\alpha^+\alpha^-$
- 1246  $+\alpha \alpha \alpha + +\alpha = \tau 1 \tau = 2\tau 1$ , reported in Fig. 7 E,F, where the parameters  $\alpha^+$ ,  $\alpha^-$  were
- 1247 computed from the slopes of the D2l (postsynaptic D2 receptors) and D1 occupancy curves  $(2\tau 1)_{occ}$
- 1248 or activation curves  $(2\tau 1)_{act}$  The change in relative reversal learning in Fig. 7 H-I was calculated as 1249 taking the difference between drug and the 'control' condition as:
- 1250  $\Delta(2\tau 1) = (2\tau 1)_{drug} (2\tau 1)_{control}.$

We simulated the effect of bromocriptine using the biophysical model for dopamine release and receptor
occupancy (Section 2, Methods). We added an additional ligand for D2 receptors to the update equations
for occupancy:

1254 
$$\frac{dOcc_{DA,r_j}(t)}{dt} = \left(1 - Occ_{DA,r_j}(t)\right) \times k_{on}^{DA,r_j} \times C_{DA}(t) - k_{off}^{DA,r_j}$$

1255 
$$\frac{dOcc_{Drug,r_j}(t)}{dt} = \left(1 - Occ_{Drug,r_j}(t)\right) \times k_{on}^{Drug,r_j} \times C_{Drug}(t) - k_{off}^{Drug,r_j}$$

1256 Where  $r_j$ : {D1, D2s, D2l}, and  $k_{on}^{Drug,D2s} = 0.02083$ ,  $k_{off}^{Drug,D2s} = 0.1$ ,  $k_{on}^{Drug,D2l} = 0.04$ ,  $k_{off}^{Drug,D2l} = 0.1$ 1257 are reported in Table 1 <sup>97</sup>.

To calculate the effects of efficiency of the drug, we calculated the activation of D2l and D2s receptors inthe following way:

1260 
$$Act_{r_i}(t) = E_{DA,r_i} \cdot Occ_{DA,r_i}(t) + E_{Drug,r_i} \cdot Occ_{Drug,r_i}(t)$$

Where  $E_{DA,r_j} = 1$  is the efficiency of dopamine on the receptors activation, and  $E_{Drug,r_j} < 1$  the efficiency of the drug, for  $r_j$ : {D1, D2s, D2l}. The parameter for D1 receptors was kept at  $E_{Drug,D1} = 0$ 

## 1263 for all simulations.

To simulate the effects of D2s activation by the drug in D2l occupancy in Fig. 7b,e,h we report the effects of  $E_{Drug,D2s} = 0$  (solid lines) and  $E_{Drug,D2s} = 0.6$  (dashed lines). To simulate the effect of the drug in D2s and D2l activation in Fig. 7c,f,i we report the effects of  $E_{Drug,D2s} = 0.6$ ,  $E_{Drug,D2l} = 0.6$ .

1267 We show how the qualitative nature of the effects of the drug in relative reversal learning still hold

1268 regardless of whether the parameter  $\tau$  is computed from the occupancy curves (Extended Data Fig. 7, Fig.

1269 7n,e,h) or the activation curves (Extended Data Fig. 8, Fig. 7c,f,i). In addition, in Supplementary Figure

1270 8-9 we show that the qualitative results still hold regardless of the choice of the efficiency parameters

1271  $E_{Drug,D2s}$  and  $E_{Drug,D2l}$ .

## 1272 **4.2. Timmer et al. (2018)**

1273 In this study<sup>25</sup> they reported a 'loss aversion' parameter ( $\lambda$  in their results).

1274 
$$SUG = (1 - \lambda) \cdot p_{gain} \cdot Gain + \lambda \cdot p_{loss} \cdot Loss$$

1275 Where SUG is the 'subjective utility' for a given option, and  $p_{gain} = p_{loss}$ .

1276 In our formulation, we assume that the task in the study is performed under steady state conditions after

1277 having learned with a learning rate ( $\tau$ ). With this assumption, the SUG at task performance is equivalent to

1278 the convergent V estimate after learning. We will show that at these steady state conditions  $(1 - \tau)$  is

1279 equivalent to  $(\lambda)$ .

1280 Starting with the solution for *V*:

1281 
$$SUG = V = \frac{\tau \cdot p_{gain} \cdot r_{gain} + (1 - \tau) \cdot (1 - p_{gain}) \cdot r_{loss}}{\tau \cdot p_{gain} + (1 - \tau) \cdot (1 - p_{gain})}$$

1282 Replacing for  $p_{gain} = 0.5$ :

1283 
$$SUG = \frac{\tau \cdot r_{gain} + (1 - \tau) \cdot r_{loss}}{\tau + (1 - \tau)}$$

1284 Given that:  $\tau + (1 - \tau) = 1$ 

<sup>¬</sup> l · <sup>¬</sup> gain <sup>¬</sup>	-(1	-i	· Floss
	a ∙ r <sub>gain</sub> †	$T \cdot r_{gain} + (1)$	$1 \cdot r_{gain} + (1 - 1)$

1286 Therefore, our model, applied to their task, gives rise to the same SUG computation, with  $\lambda$  equivalent to

1287  $(1 - \tau)$ .

1288 To generate Fig. 8F, we performed the following steps:

1289 1. We first estimated the theoretical change in baseline DA elicited by the medication. For this, we 1290 computed the equivalent  $\tau$  for the  $\lambda$  they report in the OFF and ON medication conditions 1291  $(\lambda_{OFF} = 1.51, \lambda_{ON} = 1.19)$ , using the relationship:  $(1 - \tau) = \lambda$ . We then computed the baseline 1292 DA levels that would give rise to the  $\tau_{ON}$  and  $\tau_{OFF}$ . With this, we computed the change in 1293 baseline DA ( $\Delta DA$ ) equivalent to the change  $\Delta \tau = \tau_{ON} - \tau_{OFF}$ . This  $\Delta DA$  is the theoretical 1294 change in baseline DA elicited by the medication (Fig. 8F). 1295 2. To generate Fig. 8F, we sampled a set of  $\lambda$  from a Gaussian distribution centered at a mean of  $\mu_{\lambda} = 1.51$  and a standard deviation of  $\sigma_{\lambda}^2 = 3$ , to emulate the distribution of  $\lambda_{OFF}$  they report in 1296 the OFF condition. We then computed the equivalent  $\tau$  for that set of  $\lambda$  with the relationship 1297

- 1298 above. We will call this the distribution of  $\tau'_{OFF}$ .
- 1299 3. We used the derived  $\tau'_{OFF}$  distribution to compute the equivalent dopamine levels. We imposed a 1300 change in baseline DA equal to the  $\Delta DA$  computed in the first step and computed the new set of  $\tau$ 1301 for that set of new baseline DA levels ( $\tau'_{ON}$ ). The 'drug effect in loss aversion' reported in Fig. 1302 8F is the  $\tau'_{ON} - \tau'_{OFF}$  for each sample.
- 1303 **5. Details on habenula lesion data**

## 1304 **5.1 Animals, surgery and lesions**.

The rodent data we re-analyzed here were first reported in Tian and Uchida (2015)<sup>55</sup>. Below we provide a 1305 1306 brief description of the methods. Further methodological details can be found in the original paper. !2 1307 mice were used. Bilateral habenula lesions were performed in five animals. Seven animals were in the 1308 control group including two with sham-lesion operation, one with only small contra-lateral side lesion of 1309 the medial habenula, and four animals without operations in the habenula. During surgery, a head plate 1310 was implanted on the skull, and adeno-associated virus (AAV) that express channelrhodopsin-2 (ChR2) 1311 in a Cre-dependent manner was injected into the VTA (from bregma: 3.1 mm posterior, 0.7 mm lateral, 1312 4-4.2 mm ventral). After recovery from surgery, mice were trained on the conditioning task, after which 1313 mice were randomly selected to be in lesion or sham-lesion group. Electrolytic lesions were made 1314 bilaterally using a stainless-steel electrode (15 kU, MicroProbes, MS301G) with a cathodal current of 150

- 1315 mA. Each side of the brain was lesioned at two locations (from bregma: 1.6 mm/1.9 mm posterior, 1.15
- 1316 mm lateral, 2.93 mm depth, with a 14 angle). For sham-lesion operations, no current was applied. In the
- 1317 same surgery, a microdrive containing electrodes and an optical fiber was implanted in the VTA (from
- 1318 bregma: 3.1 mm posterior, 0.7 mm lateral, 3.8-4.0 mm ventral)<sup>98</sup>.

#### 1319 **5.2 Behavioral task**

- 1320 Twelve mice were trained on a probabilistic Pavlovian task. Each trial the animal experienced one of four
- 1321 odor cues for 1 s, followed by a 1-s pause, followed by a reward (3.75 µl water), an aversive air puff or
- 1322 nothing. Odor 1 to 3 signaled a 90%, 50% and 10% probability of reward, respectively. Odor 4 signaled a
- 1323 90% probability of air puff. Odor identities were randomized across trials and included: isoamyl acetate,
- eugenol, 1-hexanol, p-cymene, ethyl butyrate, 1-butanol, and carvone (1/10 dilution in paraffin oil). Inter-
- 1325 trial intervals were exponentially distributed. An infrared beam was positioned in front of the water
- delivery spout and each beam break was recorded as one lick event. We report the average lick rate over
- 1327 the interval 500–2,000 ms after cue onset.

## 1328 **5.3 Electrophysiology**

- 1329 Recordings were made using a custom-built microdrive equipped with 200-µm-fiber optic-coupled with
- eight tetrodes. DA neurons were identified optogenetically<sup>98</sup>. A stimulus-associated spike latency test
- 1331 (SALT) algorithm<sup>99</sup> was used to determine whether light pulses significantly changed a neuron's spike
- timing.

#### 1333 5.4 Neural data analysis

- 1334 Data analyses were performed using MATLAB R2021b (Mathworks). To measure firing rates,
- peristimulus time histograms (PSTHs) were constructed using 1-ms bins. These histograms were then
- 1336 smoothed by convolving with the function  $f(t) = (1 e^{-t}) \cdot e^{-\frac{t}{\tau}}$  where  $\tau$  was a time constant set to 20
- ms as in <sup>18</sup>. 44 dopamine neurons were recorded from lesioned animals (5 animals, 30 sessions), and 45
- dopamine neurons were recorded from control animals (7 animals, 35 sessions). We pooled all the cells
- 1339 across animals in each group for analysis. Cue-evoked responses were defined as the average activity
- 1340 from 0 to 400 ms after cue onset. Outcome-evoked responses were defined as the average activity from
- 1341 2000 to 2600 ms after cue onset.
- 1342 The normalization of cue response shown in Fig. 4 was carried out following a previous work<sup>36</sup> on a per-

1343 cell basis as: 
$$c_{50}^{norm} = \frac{c_{50} - \overline{c_{10}}}{\overline{c_{90}} - \overline{c_{10}}}$$
, where  $\overline{c_{90}}$ ,  $\overline{c_{10}}$  correspond to the mean across trials within a cell for the

1344 90% and 10% probability cure responses. To derive the t-statistics in Fig. 4d, we performed a two-tailed t-

1345 test of the cell's normalized responses to the 50% cue against the average midway point between

responses to the 10% cue and responses to the 90% cue.

1347 The derivation of asymmetric scaling factors from outcome responses ( $\tau_i$ ), was carried out following <sup>36</sup>, 1348 with some modifications to adapt it to the task. The procedure is illustrated in Extended Data Fig. 3.

1349 To compute the reversal points, outcome responses were first aligned to the RPE for each trial 1350 type, computed with the true expected value of each reward distribution. Assuming a fixed reward 1351 value of 1 (arbitrary units), the expected value for the 90%, 50%, 10% reward probability trials 1352 corresponded to 0.1, 0.5, 0.9, respectively. Given this, omission responses from the 90%, 50%, 1353 10% reward probability trials correspond to RPEs of -0.9, -0.5 and -0.1. The rewarded responses 1354 from the 90%, 50%, 10% reward probability trials correspond to RPEs of 0.1, 0.5 and 0.9. The 1355 reward value is arbitrary and doesn't have an effect in this computation as it only shifts the RPE 1356 axis by a fixed amount. The reversal point for each cell  $(Z_i)$  was defined as the RPE that 1357 maximized the number of positive responses to RPEs greater than  $Z_i$  plus the number of negative 1358 responses to RPEs less than  $Z_i$ . The distribution of reversal points is reported in Extended Data 1359 Fig. 4. To obtain statistics for reliability of the computed reversal points, we partitioned the data 1360 into random halves and estimated the reversal point for each cell separately in each half. We 1361 repeated this procedure 1000 times with different random partitions, and we report the 1362 distribution of Pearson's correlation across these 1000 folds (Extended Data Fig. 4). After measuring reversal points, we fit linear functions separately to the positive and negative 1363

After measuring reversal points, we fit intear functions separately to the positive and negative domains. Given that dopamine's responses are non-linear in the reward space but present a putative utility function<sup>100</sup>, we approximated the underlying utility function from the dopamine responses to RPEs of varying magnitudes. We used these empirical utilities instead of raw RPEs for computing the slopes that correspond to  $\alpha_i^+, \alpha_i^-$ . We then computed the asymmetric scaling

1368 factors as  $\tau_i = \frac{\alpha_i^+}{\alpha_i^+ + \alpha_i^-}$ . We performed the same cross-validation procedure used for the reversal

1370 A key prediction of distributional  $RL^{36}$  is the presence of a correlation (across cells) between reversal

1371 points  $Z_i$  and asymmetric scaling factors  $\tau_i$ . To elucidate whether signatures of distributional RL were

1372 still present after lesions, we followed the procedure given by Dabney et al. (2020)<sup>36</sup> to compute this

1373 correlation. We first randomly split the data into two disjoint halves of trials. In one half, we first

- 1374 calculated reversal points  $Z_i^1$  and used them to calculate  $\alpha_i^+$ ,  $\alpha_i^-$ . In the other half, we again calculated the
- 1375 reversal points  $Z_i^2$ . The correlation we report in Extended Data Fig. 4 is between  $Z_i^2$  and  $\tau_i = \frac{\alpha_i^+}{\alpha_i^+ + \alpha_i^-}$ .

## 1376 **5.5 Model fitting to the anticipatory licking responses**

1377 For each trial we computed the average lick rate over the interval 500–2,000 ms after cue onset. For each

- 1378 model, we fit the free parameters to the lick rates using maximum likelihood estimation. The optimization
- 1379 was performed using the SciPy optimization toolbox (Python) that minimized the difference between the
- 1380 predicted lick rates and the ground truth ones, with a uniform prior distribution over the parameters. The
- 1381 fits were done considering three RL models that had between 2 and 3 parameters. The models, parameters
- and bounds used for each of them are detailed in table 2.

1383

## 1385 Tables

## 1386 **Table 1 – Biophysical model parameters**

1387

Parameter	Abbreviation	Value
DA association constant to D2 autorreceptors	$k_{on}^{D2_{term}}$	$0.3 M^{-1} s^{-1}$
DA dissociation constant to D2 autorreceptors	$k_{off}^{D2term}$	$0.003 \ s^{-1}$
DA association constant to D1 receptors	$k_{on}^{D1}$	$0.01 \ M^{-1} s^{-1}$
DA dissociation constant to D1 receptors	$k_{off}^{D1}$	$10 \ s^{-1}$
DA association constant to D2 receptors	$k_{on}^{D2}$	$0.2 M^{-1} s^{-1}$
DA dissociation constant to D2 receptors	$k_{off}^{D2}$	2 s <sup>-1</sup>
Release probability from terminals	P <sub>r</sub>	1 a.u.
Release capacity from terminals	$\gamma_{pr_n}$	2 a.u.
D2 autorreceptor efficacy	α	3 a.u.
DAT maximal uptake capacity	$V_{max}^{pr_n}$	1500 nMs <sup>-1</sup>
Michaelis-Menten parameter DAT-mediated DA uptake	K <sub>m</sub>	160 nM
Constant for dopamine removal not mediated by DAT's	K <sub>nonDAT</sub>	0.04 <i>nM</i>
Bromocriptine association constant to D2 autorreceptors	$k_{on}^{Drug,D2s}$	$0.02083 M^{-1}s^{-1}$
Bromocriptine dissociation constant to D2 autorreceptors	$k_{off}^{Drug,D2s}$	$0.1  s^{-1}$
Bromocriptine association constant to D2 receptors	$k_{on}^{Drug,D2l}$	$0.04 M^{-1}s^{-1}$
Bromocriptine dissociation constant to D2 receptors	$k_{off}^{Drug,D2l}$	$0.1  s^{-1}$

- 1388 a.u. = arbitrary units
- 1389 M = mols
- $1390 \quad s = seconds$

1391

Model	Formulation	Parameters	Parameter bounds
TD learning	$\delta = r - V$	α,β	<i>α</i> ∈ [.001,1]
	$V \leftarrow V + \alpha \cdot \delta$		$\beta \in [.1,10]$
	$Licking = \beta \cdot V$		
TD learning	$\delta = \rho \cdot r - V$	α, ρ, β	$\alpha \in [.001,1]$
sensitivity	$V \leftarrow V + \alpha \cdot \delta$		$\rho \in [.001,10]$
	$Licking = \beta \cdot V$		$\beta \in [.1,10]$
Risk sensitive	$\delta = r - V$	$\alpha^+, \alpha^-, \beta$	$\alpha^+ \in [.001,1]$
TD learning	$V \leftarrow V + \alpha^+ \cdot \delta  \text{if } \delta > 0$		$\alpha^{-} \in [.001,1]$
	$V \leftarrow V + \alpha^- \cdot \delta  \text{if } \delta < 0$		$\beta \in [.1,10]$
	$Licking = \beta \cdot V$		

1393	Table 2- Reinforcement	learning 1	models fit	to the	behavioral	data from	Tian &	Uchida
------	------------------------	------------	------------	--------	------------	-----------	--------	--------

1394

1395

# 1396 Data availability

1397 The neural data and simulation results reported in this article have been shared in a public

1398 deposit source in: <u>https://osf.io/cr5mv/?view\_only=bd13a2d2de1947699b56ce70610b0e9b</u>

1399

# 1400 Code availability

1401 The accession codes for the data as well as the code for analysis and simulations are available at:

1402 https://github.com/sandraromerop/D1D2\_Dopamine

1403

## 1405 **References**

- 1406 1. Brown, V. M., Zhu L., Solway A., Wang M., McCurry K., King-Casas B. & Chiu P. 1407 Reinforcement Learning Disruptions in Individuals With Depression and Sensitivity to 1408 Symptom Change Following Cognitive Behavioral Therapy. JAMA Psychiatry 78, 1113– 1409 1122 (2021). 1410 2. Groman, S. M., Thompson, S. L., Lee, D. & Taylor, J. R. Reinforcement learning detuned in 1411 addiction: integrative and translational approaches. Trends Neurosci. 45, 96–105 (2022). 1412 3. Ligneul, R., Sescousse, G., Barbalat, G., Domenech, P. & Dreher, J.-C. Shifted risk 1413 preferences in pathological gambling. Psychol. Med. 43, 1059–1068 (2013). 1414 4. Mason, L., O'Sullivan, N., Bentall, R. P. & El-Deredy, W. Better than I thought: positive 1415 evaluation bias in hypomania. PLoS One 7, e47754 (2012). 1416 5. Pizzagalli, D. A., Iosifescu, D., Hallett, L. A., Ratner, K. G. & Fava, M. Reduced hedonic 1417 capacity in major depressive disorder: evidence from a probabilistic reward task. J. 1418 Psychiatr. Res. 43, 76–87 (2008). 1419 6. Verdejo-Garcia, A., Chong, T. T.-J., Stout, J. C., Yücel, M. & London, E. D. Stages of 1420 dysfunctional decision-making in addiction. *Pharmacol. Biochem. Behav.* 164, 99–105 1421 (2018). 1422 7. Lim, T. V., Cardinal, R. N., Bullmore, E. T., Robbins, T. W. & Ersche, K. D. Impaired 1423 Learning From Negative Feedback in Stimulant Use Disorder: Dopaminergic Modulation. 1424 *Int. J. Neuropsychopharmacol.* **24**, 867–878 (2021). 1425 8. Schönfelder, S., Langer, J., Schneider, E. E. & Wessa, M. Mania risk is characterized by an 1426 aberrant optimistic update bias for positive life events. J. Affect. Disord. 218, 313–321 1427 (2017). 1428 9. Dayan, P. & Daw, N. D. Decision theory, reinforcement learning, and the brain. Cogn. Affect. 1429 *Behav. Neurosci.* 8, 429–453 (2008). 1430 10. Katahira, K. The relation between reinforcement learning parameters and the influence of
  - reinforcement history on choice behavior. J. Math. Psychol. 66, 59–69 (2015).

- 1432 11. Sutton, R. S. & Barto, A. G. *Reinforcement Learning: An Introduction*. (Bradford Books,
  1433 2018).
- 1434 12. Maia, T. V. & Frank, M. J. From reinforcement learning models to psychiatric and
  1435 neurological disorders. *Nat. Neurosci.* 14, 154–162 (2011).
- 1436 13. Eldar, E., Rutledge, R. B., Dolan, R. J. & Niv, Y. Mood as Representation of Momentum.
  1437 *Trends Cogn. Sci.* 20, 15–24 (2016).
- 1438 14. Rutledge, R. B., Skandali, N., Dayan, P. & Dolan, R. J. A computational and neural model of
  1439 momentary subjective well-being. *Proc. Natl. Acad. Sci. U. S. A.* 111, 12252–12257 (2014).
- 1440 15. Floresco, S. B., West, A. R., Ash, B., Moore, H. & Grace, A. A. Afferent modulation of
- 1441 dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. *Nat.*1442 *Neurosci.* 6, 968–973 (2003).
- 1443 16. Wang, Y., Toyoshima, O., Kunimatsu, J., Yamada, H. & Matsumoto, M. Tonic firing mode
  1444 of midbrain dopamine neurons continuously tracks reward values changing moment-by1445 moment. *Elife* 10, (2021).
- 1446 17. Schultz, W., Dayan, P. & Montague, P. R. A neural substrate of prediction and reward.
  1447 *Science* 275, 1593–1599 (1997).
- 1448 18. Eshel, N., Tian, J., Bukwich, M. & Uchida, N. Dopamine neurons share common response
  1449 function for reward prediction error. *Nat. Neurosci.* 19, 479–486 (2016).
- 1450 19. Steinberg, E. Keiflin, R., Boivin, J., Witten I., Deisseroth K. & Janak P. A causal link
  1451 between prediction errors, dopamine neurons and learning. *Nat. Neurosci.* 16, 966–973
  1452 (2013).
- 20. Waelti, P., Dickinson, A. & Schultz, W. Dopamine responses comply with basic assumptions
  of formal learning theory. *Nature* 412, 43–48 (2001).
- 1455 21. Korn, C. W., Sharot, T., Walter, H., Heekeren, H. R. & Dolan, R. J. Depression is related to
  1456 an absence of optimistically biased belief updating about future life events. *Psychol. Med.* 44,
  1457 579–592 (2014).
- 1458 22. Rutledge, R. B., Lazzaro, S. C., Lau, B., Myers, C. E., Gluck, M. A., & Glimcher, P. W.
- Dopaminergic drugs modulate learning rates and perseveration in Parkinson's patients in a
  dynamic foraging task. *J. Neurosci.* 29, 15104–15114 (2009).

- 1461 23. Frank, M. J., Seeberger, L. C. & O'Reilly, R. C. By carrot or by stick: Cognitive
  1462 reinforcement learning in Parkinsonism. *Science* 306, 1940–1943 (2004).
- 1463 24. Cools, R., Frank M.J., Gibbs S., Miyakawa A., Jagust W. & D'Esposito M. Striatal
- 1464 dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic
  1465 drug administration. *J. Neurosci.* 29, 1538–1543 (2009).
- 1466 25. Timmer, M. H. M., Sescousse, G., van der Schaaf, M. E., Esselink, R. A. J. & Cools, R.
- 1467 Reward learning deficits in Parkinson's disease depend on depression. *Psychol. Med.* 47,
  1468 2302–2311 (2017).
- 1469 26. Gradin, V. B., Kumar, P., Waiter, G., Ahearn, T., Stickle, C., Milders, M., Reid, I., Hall, J.,
- 1470 & Steele, J. D. Expected value and prediction error abnormalities in depression and
  1471 schizophrenia. *Brain* 134, 1751–1764 (2011).
- 1472 27. Kumar, P., Waiter, G., Ahearn, T., Milders, M., Reid, I., & Steele, J. D. Abnormal temporal
  1473 difference reward-learning signals in major depression. *Brain* 131, 2084–2093 (2008).
- 1474 28. Pizzagalli, D. A., Holmes, A. J., Dillon, D. G., Goetz, E. L., Birk, J. L., Bogdan, R.,
- Dougherty, D. D., Iosifescu, D. V., Rauch, S. L., & Fava, M. Reduced caudate and nucleus
  accumbens response to rewards in unmedicated individuals with major depressive disorder.
- 1477 *Am. J. Psychiatry* **166**, 702–710 (2009).
- 1478 29. Robinson, O. J., Cools, R., Carlisi, C. O., Sahakian, B. J. & Drevets, W. C. Ventral striatum
- response during reward and punishment reversal learning in unmedicated major depressive
  disorder. *Am. J. Psychiatry* 169, 152–159 (2012).
- 30. Collins, A. G. E. & Frank, M. J. Opponent actor learning (OpAL): modeling interactive
  effects of striatal dopamine on reinforcement learning and choice incentive. *Psychol. Rev.*1483 121, 337–366 (2014).
- 1484 31. Frank, M. J. Dynamic Dopamine Modulation in the Basal Ganglia: A Neurocomputational
  1485 Account of Cognitive Decits in Medicated and Non-medicated Parkinsonism. *J. Cogn.*1486 *Neuroci.* 17, 51-72 (2005).
- 1487 32. Mikhael, J. G. & Bogacz, R. Learning Reward Uncertainty in the Basal Ganglia. *PLoS*1488 *Comput. Biol.* 12, 1–28 (2016).

- 1489 33. Yagishita, S., Hayashi- Takagi, A., Ellis-Davies, G.C.R., Urakubo, H., Ishii, S. & Kasai, H.
- A critical time window for dopamine actions on the structural plasticity of dendritic spines. *Science* 345, 1616–1620 (2014).
- 34. Iino, Y. Sawada, T., Yamaguchi, K. *et al.* Dopamine D2 receptors in discrimination learning
  and spine enlargement. *Nature* 579, 555–560 (2020).
- 1494 35. Lee, S. J., Lodder, B., Chen, Y., Patriarchi, T., Tian, L & Sabatini, B. Cell-type-specific
- asynchronous modulation of PKA by dopamine in learning. *Nature* **590**, 451–456 (2021).
- 36. Dabney, W., Kurth-Nelson, Z., Uchida, N., Starkweather, C., Hassabis, D., Munos, R. &
  Botvinick, M. A distributional code for value in dopamine- based reinforcement learning. *Nature* 1, (2019).
- 37. Bellemare, M. G., Dabney, W. & Munos, R. A distributional perspective on reinforcement
  learning. *34th International Conference on Machine Learning, ICML 2017* 1, 693–711
  (2017).
- 1502 38. Lowet, A. S., Zheng, Q., Matias, S., Drugowitsch, J. & Uchida, N. Distributional
  1503 Reinforcement Learning in the Brain. *Trends Neurosci.* 43, 980–997 (2020).
- 39. Rowland, M., Dadashi, R., Kumar, S., Munos, R., Bellemare, M. G. & Dabney, W. Statistics
  and samples in distributional reinforcement learning. *36th International Conference on Machine Learning, ICML 2019* 6, 9727–9750 (2019).
- 40. Mihatsch, O. & Neuneier, R. Risk-sensitive reinforcement learning. *Mach. Learn.* 49, 267–
  290 (2002).
- 1509 41. Bellemare, M. G. & Dabney, W. Distributional reinforcement learning. (MIT Press, 2023).
- 42. Jones, M. C. Expectiles and M-quantiles are quantiles. *Stat. Probab. Lett.* 20, 149–153
  (1994).
- 43. Houk, J., Davis, J., & Beiser, D. *Models of information processing in the basal ganglia*.
  (Bradford Books, 2019).
- 44. Gerfen, C. The neostriatal mosaic: Multiple levels of compartmental organization in the basal
  ganglia. *Annu. Rev. Neurosci.* 15, 285–320 (1992).

- 45. Smith, Y., Bevan, M. D., Shink, E. & Bolam, J. P. Microcircuitry of the direct and indirect
  pathways of the basal ganglia. *Neuroscience* 86, 353–387 (1998).
- 46. Kravitz, A. V., Tye, L. D. & Kreitzer, A. C. Distinct roles for direct and indirect pathway
  striatal neurons in reinforcement. *Nat. Neurosci.* 15, 816–818 (2012).
- 47. Reynolds, J. N. J., Hyland, B. I. & Wickens, J. R. A cellular mechanism of reward-related
  learning. *Nature* 413, 67–70 (2001).
- 48. Gerfen, C. R. & Surmeier, D. J. Modulation of striatal projection systems by dopamine. *Annu. Rev. Neurosci.* 34, 441–466 (2011).
- 49. Richfield, E. K., Penney, J. B. & Young, A. B. Anatomical and affinity state comparisons
  between dopamine D1 and D2 receptors in the rat central nervous system. *Neuroscience* 30,
  767–777 (1989).
- 1527 50. Rice, M. E. & Cragg, S. J. Dopamine spillover after quantal release: Rethinking dopamine
  1528 transmission in the nigrostriatal pathway. *Brain Res. Rev.* 58, 303–313 (2008).
- 1529 51. Gonon, F. G. & Buda, M. J. Regulation of dopamine release by impulse flow and by
  1530 autoreceptors as studied by in vivo voltammetry in the rat striatum. *Neuroscience* 14, 765–
  1531 774 (1985).
- 1532 52. Dodson, P. D., Dreyer, J. K., Jennings, K. A., Syed, E. C. J., Wade-Martins, R., Cragg, S. J.,
- Bolam, J. P. & Magill, P. J. Representation of spontaneous movement by dopaminergic
  neurons is cell-type selective and disrupted in parkinsonism. *Proc. Natl. Acad. Sci. U. S. A.*
- 1535 **113**, E2180–E2188 (2016).
- 1536 53. Marcott, P. F., Mamaligas, A. A. & Ford, C. P. Phasic dopamine release drives rapid
  1537 activation of striatal D2-receptors. *Neuron* 84, 164–176 (2014).
- 1538 54. Jaskir, A. & Frank, M. J. On the normative advantages of dopamine and striatal opponency
  1539 for learning and choice. *Elife* (2023).
- 1540 55. Tian, J. & Uchida, N. Habenula Lesions Reveal that Multiple Mechanisms Underlie
  1541 Dopamine Prediction Errors. *Neuron* 87, 1304–1316 (2015).
- 1542 56. Cui, Y., Yang, Y., Ni, Z., Dong, Y., Cai, G., Foncelle, A., Ma, S., Sang, K., Tang, S., Li, Y.,
- 1543 Shen, Y., Berry, H., Wu, S. & Hu, H. Astroglial Kir4.1 in the lateral habenula drives
- neuronal bursts in depression. *Nature* **554**, 323–327 (2018).

- 1545 57. Li, B., Piriz, J., Mirrione, M., Chung, C., D. Proulx, C., Schulz, D., Henn, F. & Malinow, R.
- 1546 Synaptic potentiation onto habenula neurons in the learned helplessness model of depression.
  1547 *Nature* 470, 535–541 (2011).
- 1548 58. Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S. & Hu, H. Ketamine blocks bursting in
  1549 the lateral habenula to rapidly relieve depression. *Nature* 554, 317–322 (2018).
- 1550 59. Dreyer, J. K., Herrik, K. F., Berg, R. W. & Hounsgaard, J. D. Influence of phasic and tonic
  1551 dopamine release on receptor activation. *J. of Neurosci.* **30**, 14273–14283 (2010).
- 1552 60. Mikhael, J. G., Lai, L. & Gershman, S. J. *Rational inattention and tonic dopamine*. *PLoS*1553 *Comput. Biol.* **17** e1008659 (2021).
- 1554 61. Vingerhoets, F. J., Snow, B. J., Schulzer, M., Morrison, S., Ruth, T. J., Holden, J. E., Cooper,
- S. & Calne, D. B. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography
  in normal human subjects. *J. Nucl. Med.* 35, 18–24 (1994).
- 1557 62. Cools, R., Gibbs, S. E., Miyakawa, A., Jagust, W. & D'Esposito, M. Working memory
  1558 capacity predicts dopamine synthesis capacity in the human striatum. *J. Neurosci.* 28, 1208–
  1559 1212 (2008).
- 63. Hoffmann, I. S. & Cubeddu, L. X. Differential effects of bromocriptine on dopamine and
  acetylcholine release modulatory receptors. *J. Neurochem.* 42, 278–282 (1984).
- 1562 64. Tissari, A. H., Rossetti, Z. L., Meloni, M., Frau, M. I. & Gessa, G. L. Autoreceptors mediate
  1563 the inhibition of dopamine synthesis by bromocriptine and lisuride in rats. *Eur. J.*1564 *Pharmacol.* 91, 463–468 (1983).
- 1565 65. Lieberman, A. Depression in Parkinson's disease -- a review. *Acta Neurol. Scand.* 113, 1–8
  1566 (2006).
- 1567 66. Leentjens, A. F. G., Van den Akker, M., Metsemakers, J. F. M., Lousberg, R. & Verhey, F.
- R. J. Higher incidence of depression preceding the onset of Parkinson's disease: a register
  study. *Mov. Disord.* 18, 414–418 (2003).
- 1570 67. Nilsson, F. M., Kessing, L. V., Sørensen, T. M., Andersen, P. K. & Bolwig, T. G. Major
  1571 depressive disorder in Parkinson's disease: a register-based study. *Acta Psychiatr. Scand.*1572 106, 202–211 (2002).

- 1573 68. Remy, P., Doder, M., Lees, A., Turjanski, N. & Brooks, D. Depression in Parkinson's
  1574 disease: loss of dopamine and noradrenaline innervation in the limbic system. *Brain* 128,
  1575 1314–1322 (2005).
- 1576 69. Weintraub, D., Newberg, A. B., Cary, M. S., Siderowf, A. D., Moberg, P. J., Kleiner-Fisman,
- 1577 G., Duda, J. E., Stern, M. B., Mozley, D. & Katz, I. R. Striatal dopamine transporter imaging
- 1578 correlates with anxiety and depression symptoms in Parkinson's disease. J. Nucl. Med. 46,
  1579 227–232 (2005).
- 70. Kish, S. J., Shannak, K. & Hornykiewicz, O. Uneven pattern of dopamine loss in the striatum
  of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. *N. Engl. J. Med.* **318**, 876–880 (1988).
- 1583 71. Timmer, M. H. M., Sescousse, G., Esselink, R. A. J., Piray, P. & Cools, R. Mechanisms
  1584 Underlying Dopamine-Induced Risky Choice in Parkinson's Disease With and Without
  1585 Depression (History). *Comput Psychiatr* 2, 11–27 (2018).
- 1586 72. Hikida, T., Kimura, K., Wada, N., Funabiki, K. & Nakanishi Shigetada, S. Distinct Roles of
  1587 Synaptic Transmission in Direct and Indirect Striatal Pathways to Reward and Aversive
  1588 Behavior. *Neuron* 66, 896–907 (2010).
- 1589 73. Hikida, T., Yawata, S., Yamaguchi, T., Danjo, T., Sasaoka, T., Wang, Y. & Nakanishi S.
  1590 Pathway-specific modulation of nucleus accumbens in reward and aversive behavior via
  1591 selective transmitter receptors. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 342–347 (2013).
- 74. Danjo, T., Yoshimi, K., Funabiki, K., Yawata, S. & Nakanishi, S. Aversive behavior induced
  by optogenetic inactivation of ventral tegmental area dopamine neurons is mediated by
  dopamine D2 receptors in the nucleus accumbens. *Proc. Natl. Acad. Sci. U. S. A.* 111, 6455–
  6460 (2014).
- 1596 75. Yamaguchi, T., Goto, A., Nakahara, I., Yawata, S., Hikida, T., Matsuda, M., Funabiki, K &
  1597 Nakanishi, S. Role of PKA signaling in D2 receptor-expressing neurons in the core of the
  1598 nucleus accumbens in aversive learning. *Proc. Natl. Acad. Sci. U. S. A.* 112, 11383–11388
  1599 (2015).
- 1600 76. Bayer, H. M. & Glimcher, P. W. Midbrain dopamine neurons encode a quantitative reward
  1601 prediction error signal. *Neuron* 47, 129–141 (2005).

- 1602 77. Hart, A. S., Rutledge, R. B., Glimcher, P. W. & Phillips, P. E. M. Phasic dopamine release in
- 1603 the rat nucleus accumbens symmetrically encodes a reward prediction error term. J.
- 1604 *Neurosci.* **34**, 698–704 (2014).
- 1605 78. Grace, A. A. Dysregulation of the dopamine system in the pathophysiology of schizophrenia
  1606 and depression. *Nat. Rev. Neurosci.* 17, 524–532 (2016).
- 1607 79. Anstrom, K. K., Miczek, K. A. & Budygin, E. A. Increased phasic dopamine signaling in the
  1608 mesolimbic pathway during social defeat in rats. *Neuroscience* 161, 3–12 (2009).
- 1609 80. Razzoli, M., Andreoli, M., Michielin, F., Quarta, D. & Sokal, D. M. Increased phasic activity
- 1610 of VTA dopamine neurons in mice 3 weeks after repeated social defeat. *Behav. Brain Res.*
- **218**, 253–257 (2011).
- 1612 81. Markovic, T., Pederson, C. E., Massaly, N., Vachez, Y., Ruyle, B., Murphy, C. A.,
- 1613 Abiraman, K., Hoon Shin, J., Garcia, J. H., Jean Yoon, H., Alvarez, V. A., Bruchas, M. R.,
- 1614 Creed, M. C. & Moron, J. A. Pain induces adaptations in ventral tegmental area dopamine
  1615 neurons to drive anhedonia-like behavior. *Nat. Neurosci.* 24, 1601–1613 (2021).
- 1616 82. Guo, Z., Li, S., Wu, J., Zhu, X. & Zhang, Y. Maternal deprivation increased vulnerability to
  1617 depression in adult rats through DRD2 promoter methylation in the ventral tegmental area.
  1618 *Front. Psychiatry* 13, 827667 (2022).
- 1619 83. Peng, B., Hu, Q., Liu, J., Guo, S., Borgland, S. L.& Liu, S. Corticosterone attenuates
- reward-seeking behavior and increases anxiety via D2 receptor signaling in ventral tegmental
  area dopamine neurons. *J. Neurosci.* 41, 1566–1581 (2021).
- 1622 84. Tye, K. M., Mirzabekov, J. J., Warden, M. R., Ferenczi, E. A., Tsai, H-C., Finkelstein, J.,
- 1623 Kim, S-Y., Adhikari, A., Thompson, K. R., Andalman A. S., Gunaydin, L. A., Witten I. &
- 1624 Deisseroth K. Dopamine neurons modulate neural encoding and expression of depression-
- 1625 related behaviour. *Nature* **493**, 537–541 (2013).
- 1626 85. Baek, K., Kwon, J., Chae, J. H., Chung, Y. A., Kralik, J. D., Min, J. A., Huh, H., Choi, K.
- 1627 M., Jang, K. I., Lee, N. B., Kim, S., Peterson, B. S., & Jeong, J. Heightened aversion to risk
- and loss in depressed patients with a suicide attempt history. *Sci. Rep.* **7**, 11228 (2017).

- 1629 86. Smoski, M. J., Lynch, T. R., Rosenthal, M. Z., Cheavens, J. S., Chapman, A. L., & Krishnan,
- 1630 R. R. Decision-making and risk aversion among depressive adults. *J. Behav. Ther. Exp.*1631 *Psychiatry* **39**, 567–576 (2008).
- 1632 87. van Holst, R. J., Sescousse, G., Janssen, L. K., Janssen, M., Berry, A. S., Jagust, W. J., &
- 1633 Cools, R. Increased Striatal Dopamine Synthesis Capacity in Gambling Addiction. *Biol.*
- 1634 *Psychiatry* **83**, 1036–1043 (2018).
- 1635 88. Cools, R., Altamirano, L. & D'Esposito, M. Reversal learning in Parkinson's disease
  1636 depends on medication status and outcome valence. *Neuropsychologia* 44, 1663–1673
  1637 (2006).
- 1638 89. Cools, R., Barker, R. A., Sahakian, B. J. & Robbins, T. W. Enhanced or impaired cognitive
  1639 function in Parkinson's disease as a function of dopaminergic medication and task demands.
  1640 *Cereb. Cortex* 11, 1136–1143 (2001).
- 90. Cools, R., Barker, R. A., Sahakian, B. J. & Robbins, T. W. L-Dopa medication remediates
  cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. *Neuropsychologia* 41, 1431–1441 (2003).
- 1644 91. Swainson, R., Rogers, R. D., Sahakian, B. J., Summers, B. A., Polkey, C. E., & Robbins, T.
- 1645 W. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal
- 1646 or temporal lobe lesions: possible adverse effects of dopaminergic medication.
- 1647 *Neuropsychologia* **38**, 596–612 (2000).
- 1648 92. Cox, S. M., Frank, M. J., Larcher, K., Fellows, L. K., Clark, C. A., Leyton, M., & Dagher, A.
  1649 Striatal D1 and D2 signaling differentially predict learning from positive and negative
  1650 outcomes. *Neuroimage* 109, 95–101 (2015).
- 1651 93. Savitz, J. B. & Drevets, W. C. Neuroreceptor imaging in depression. *Neurobiol. Dis.* 52, 49–
  1652 65 (2013).
- 1653 94. Rescorla, R. A. & Wagner, A. R. A theory of Pavlovian conditioning: Variations in the
- 1654 *effectiveness of reinforcement and nonreinforcement, Classical Conditioning II.* 64–99
- 1655 (1972).

- 1656 95. Kim, H. R., Malik, A. N., Mikhael, J. G., Bech, P., Tsutsui-Kimura, I., Sun, F., Zhang, Y., Li,
- Y., Watabe-Uchida, M., Gershman, S. J. & Uchida, N. A unified framework for dopamine
  signals across timescales. *Cell* 183, 1600-1616.e25 (2020).
- 1659 96. Bertsekas, D. P. & Tsitsiklis, J. Neuro-Dynamic Programming. (Athena Scientific, 1996).
- 1660 97. Mierau, J., Schneider, F. J., Ensinger, H. A., Chio, C. L., Lajiness, M. E., & Huff, R. M.
- Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4
  receptors. *Eur. J of Pharmac.* 290, 29-36 (1995).
- 1663 98. Cohen, J. Y., Haesler, S., Vong, L., Lowell, B. B. & Uchida, N. Neuron-type-specific signals
  1664 for reward and punishment in the ventral tegmental area. *Nature* 482, 85–88 (2012).
- 99. Kvitsiani, D., Ranade, S., Hangya, B., Taniguchi, H., Huang, J. Z. & Kepec, A. Distinct
  behavioural and network correlates of two interneuron types in prefrontal cortex. *Nature* 498,
  363–366 (2013).
- 100. Stauffer, W. R., Lak, A. & Schultz, W. Dopamine reward prediction error responses reflect
   marginal utility. *Curr. Biol.* 24, 2491–2500 (2014).
- 1670
- 1671
- 1672
- 1673
- 1674

# 1675 Acknowledgements

1676	We thank Ju Tian for providing the data used in this study; Jakob Dreyer for making the
1677	biophysical model available for open-source use; Roshan Cools, Peter Dayan and Sam Gershman
1678	for valuable feedback on the manuscript; Dan Polley, Mark Andermann and Elizabeth Phelps for
1679	mentorship and helpful discussions. We thank Bernardo Sabatini for discussions, and Isobel
1680	Green, Paul Masset, Mitsuko Watabe-Uchida and all the rest of the Uchida lab members for
1681	helpful comments at the different stages of this work. This work is supported by NIH BRAIN
1682	Initiative grants (R01NS116753, U19NS113201), the Simons Collaboration on Global Brain,
1683	and the Bipolar Disorder Seed Grant from the Harvard Brain Science Institute.
1684	
1685	Author information
1686	Contributions
1687	S.R.P. and N.U. conceived the project. S.R.P performed the modeling work. S.R.P. wrote the
1688	first draft and S.R.P and N.U. edited the paper.
1689	
1690	Corresponding author
1691	Correspondence to Naoshige Uchida (uchida@mcb.harvard.edu) and Sandra Romero Pinto
1692	(sromeropinto@g.harvard.edu).
1693	
1694	
1695	
1696	Competing interest statement
1697	The authors declare no competing interests.
1698	

## 1700 Figures

1701



# 1702 **Figure 1 | Reinforcement learning models.**

1703	<b>a</b> . Traditional reinforcement learning with a single learning rate ( $\alpha$ ) for both positive and
1704	negative RPEs ( $\delta$ ) for the value updates (left). This update rule makes value estimate (V)
1705	converge on the expected value of the reward distribution (middle). When the reward probability
1706	is varied (i.e., for Bernoulli distributions), the $V$ at convergence scales linearly with the reward
1707	probability (right).

1708 **b**. Risk-sensitive reinforcement learning with different learning rates  $(\alpha^+, \alpha^-)$  for positive and 1709 negative RPEs, respectively (left). This update rule makes value estimate (*V*) converge on the 1710 quantities that are higher or lower than the expected value of the reward distribution (middle). As 1711 the reward probabilities are varied, the convexity of the convergent value *V* changes depending

- 1712 on the asymmetry between  $\alpha^+$  and  $\alpha^-$  (Methods 1.3.3). The level of the bias is determined by
- 1713 the asymmetric learning rate parameter  $\tau$  (right).
- 1714 **c**. Distributional reinforcement learning contains a set of value predictors  $(V_i)$  each with a given
- 1715 learning rate for positive and negative RPEs ( $\alpha_i^+, \alpha_i^-$ , respectively) (left). This makes each value

- 1716 predictor converge on the quantity equal to the  $\tau_i$ -th expectile of the reward distribution. Thus,
- 1717 each value  $V_i$  represents an expectile, and together the set of  $V_i$  represents the entire distribution
- 1718 (Methods 1.2) (right).

1719



#### 1722 Figure 2 | Biologically inspired reinforcement learning model.

1723 **a**. Schematic of the basal ganglia circuitry. Dopaminergic neurons in the VTA modulate

1724 plasticity at the level of the cortico-striatal synapses on SPNs in the NAc. The SPNs are

subdivided depending on the dopamine receptor type they express (D1R or D2R).

1726 **b**. Dose-occupancy curves for the D1R and D2R describing receptor occupancies as a function of

1727 dopamine concentrations. The curves are shifted between each other due to the different

affinities of the receptors. The arrows represent 3-fold increase ("burst") and decrease ("pause)"

in dopamine concentrations, which causes left-ward or right-ward shifts of the same magnitudes

in the log-scale.

1721

1731 c. Schematic of the plasticity rules of VTA-NAc circuitry<sup>33–35</sup>. Transient increases in dopamine,

1732 caused by bursts in firing rate of dopamine neurons, generates increases in PKA activity in D1R-

1733 expressing SPNs, leading to LTP in the cortico-striatal synapses. Transient decreases in

dopamine, caused by pauses in firing rate of dopamine neurons, generates increases in PKA

- activity in D2R-expressing SPNs, leading to LTP in the cortico-striatal synapses.
- 1736 **d**. Schematic and equations of biologically inspired reinforcement learning model<sup>32</sup>
- 1737 VTA, ventral tegmental area; NAc, nucleus accumbens; SPN, spiny projection neurons; D1R,
- 1738 D1-type dopamine receptor; D2R, D2-type dopamine receptor; PKA, protein kinase A; LTP,
- 1739 long-term potentiation.



## 1741 Figure 3 | Potential mechanisms for asymmetric learning.

1742 **a**. Schematic of the mechanism by which increases or decreases in baseline dopamine modulates

- the degree to which bursts and pauses in dopamine causes changes in D1R and D2R occupancy.
- 1744 Increases in baseline dopamine makes dopamine pauses to cause greater decreases in D2R
- 1745 occupancy than the increases in D1R occupancy caused by dopamine bursts. Conversely,
- 1746 decreases in dopamine, makes dopamine bursts to cause smaller increases in D1R occupancy
- than the decreases in D2R occupancy caused by dopamine pauses.
1748 **b**. Schematic of the change in receptor occupancies in D1R and D2R, for a given transient

- 1749 increase ('burst') or decrease ('pause') in dopamine, receptively. A pause and a burst in
- 1750 dopamine correspond to  $\delta < 0$  and  $\delta > 0$  in the model. The slope is modulated by the baseline
- dopamine (colormap) and corresponds to the receptor's sensitivity to dopamine transients.
- 1752 c. Receptor sensitivity for D1R and D2R as a function of baseline dopamine. In Model 1, we
- assume that the receptor sensitivity acts as a scaling factor on the PKA activity induced by burst
- 1754 and pauses. That is,  $PKA_{D1} \propto \alpha^+ \cdot \delta \cdot \mathbf{1}_{\delta > 0}$  and  $PKA_{D2} \propto \alpha^- \cdot \delta \cdot \mathbf{1}_{\delta < 0}$ .
- 1755 **d**. Asymmetric scaling factor ( $\tau$ ) as a function of baseline dopamine. Colors depict how
- 1756 'optimistic' or 'pessimistic' the convergent value estimate will be when learning with a given  $\tau$ .
- 1757 e. Model 2. Left, the relationship between dopamine reward responses (spikes/s) and RPEs. The
- 1758 slopes of these response functions correspond to the asymmetric learning rates  $(\alpha^+, \alpha^-)$  for
- 1759 positive and negative RPEs, respectively. Colors depict how 'optimistic' or 'pessimistic' the
- 1760 convergent value estimate will be when learning with a given asymmetric scaling factor.

1761



1763

1764 Figure 4 | Habenula lesions leads to optimistic reward-seeking behavior and cue-evoked
1765 responses in dopamine neurons.

a. Schematic of the experiment performed by Tian and Uchida  $(2015)^{55}$ . Animals were trained in a classical conditioning task in which 3 odor cues predicted rewards of different probabilities (10%, 50%, 90%) and one odor cue predicted 80% probability of an air puff. Animals then underwent habenula (n = 5) or sham (n = 7) lesions and trained on the task again. The neural recordings were performed from optotagged VTA dopamine neurons once behavior stabilized.

- 1771 **b**. Anticipatory licking across sessions after lesions (left,). There was a significant increase in
- 1772 anticipatory licking to the 10% (U-statistic = -2.895, P = 0.003792, two-sided Mann-Whitney U-
- 1773 test), 50% (U-statistic = -5.579,  $P < 1 \ge 10^{-9}$ , two-sided Mann-Whitney U-test) and 90% (U-

1774 statistic = -3.487, P = 0.00048, two-sided Mann-Whitney U-test) cues (n = 31 for control n = 30

- 1775 for lesion) that results from progressive changes across sessions. The anticipatory licking curves
- 1776 show a linear scaling with reward probability in the control group, and a convex curve for the
- 1777 lesion group (mean  $\pm$  s.e.m across animals, U-statistic = -6.444,  $P < 1 \times 10^{-}$ , two-sided Mann-
- 1778 Whitney U-test for the 50% cue normalized response). These curves are predicted by RL agents
- 1779 with symmetric and asymmetric ( $\alpha^+ > \alpha^-$ ) learning rates for the control and lesion groups,
- 1780 respectively, assuming a linear mapping between anticipatory licking and value prediction.
- 1781 c. RL model fits to the anticipatory licking on a trial-by-trial basis using a risk-sensitive RL
- 1782 models that allows for separate learning rates of positive and negative RPEs. Each dot represents
- 1783 a session (n = 35 control, n = 30 lesion) and each color a mouse (n = 7 control, n = 5 lesion). The
- 1784 fits show a significant difference in the learning rates between control and lesion groups (U-

1785 statistic = -4.679,  $P < 1.0 \times 10^{-5}$ , pooling sessions across mice in each group).

- 1786 **d**. Cue-evoked dopamine responses from opto-tagged VTA dopamine neurons (mean  $\pm$  s.e.m 1787 across neurons, n = 45 control group, n = 44 lesion group). There was a decrease in the absolute 1788 magnitude of responses to the 90% cue (U-statistic = 3.249, P = 0.0011, two-sided Mann-1789 Whitney U-test) after habenula lesions (left). The normalized cue-evoked responses show the 1790 similar pattern as the normalized anticipatory-licking with a linear and convex function for the 1791 control and lesion groups, respectively, with a significant increase in normalized response to the 1792 50% cue after lesions (U-statistic = -3.824, P = 0.000131, two-sided Mann-Whitney U-test) 1793 These curves are predicted by agents with symmetric and asymmetric learning rates for control 1794 and lesion groups, respectively.
- 1795 e. Distribution of t-statistics comparing the cue-evoked response to the linear interpolation point
- between the 90% and 10% cue-evoked responses for each dopamine neuron. The distribution of
- 1797 t-statistics for the control and lesion cases was wider than what is expected from random noise
- 1798 (Monte Carlo test for standard deviation different from zero: P = 0.0222 control, P = 0.0217
- 1799 lesion, 1000 batches). The distribution was shifted to values larger than 0 in the lesion case
- 1800 (Monte Carlo test for mean larger than zero: P = 1 control, P = 0.022 lesion, 1000 batches)
- 1801 indicative of an optimistic bias in the distribution. The lesion group distribution was also
- 1802 significantly shifted to higher values with respect to the control group distribution (U-statistic =
- 1803 -2.815, P = 0.0024, single-sided Mann-Whitney U-test). Arrow heads: the mean of the *t*-
- 1804 statistics.

- 1805 **f**. Example of *t*-statistics calculations for dopamine neurons taken from the control group (mean
- 1806  $\pm$  s.e.m across trials). A *t*-statistic value close to 0 indicates linear scaling of cue-evoked
- 1807 responses with reward probability; a *t*-statistics value lower or greater than 0 indicates a concave
- 1808 or convex function of cue-evoked responses against reward probability, indicative of a
- 1809 pessimistic or an optimistic bias, respectively.

1810



Figure 5 | Model 2 cannot explain optimistic biases in behavior and cue-evoked dopamine
responses of habenula lesioned animals.

1815 **a**. Possible changes in habenula lesion mice that could explain optimistic biases based on Model

1816 2. At the level of the population dopamine responses, an optimistic bias can be caused by an

- 1817 increase in the slope of the average reward responses to positive RPEs and/or a decrease in the
- 1818 slope of the average reward responses to negative RPEs.

- 1819 **b**. At the level of the distribution of individual dopamine neuron responses, an optimistic bias
- 1820 can be caused by an overall increase in the mean of the distribution of asymmetric scaling factors
- 1821  $(\tau_i)$ , computed from each individual neuron response function.

1822 c. Observed reward responses as a function of RPEs, averaged across the population of dopamine

- 1823 neurons for the control and lesion groups (left, mean  $\pm$  s.e.m across neurons, n = 45 control
- 1824 group, n = 44 lesion group). There was a significant decrease in the reward responses for the
- 1825 50% cue (U-statistic = 3.726, P = 0.000195, two-sided Mann-Whitney U-test) and 90% cue (U-
- 1826 statistic = 2.987, P = 0.00281, two-sided Mann-Whitney U-test), and for the omission responses
- 1827 for the 90% cue (U-statistic = -4.940,  $P < 10^{-4}$ , two-sided Mann-Whitney U-test). Distribution of
- 1828 asymmetric scaling factors ( $\tau$ ), computed from the average response function over the recorded
- 1829 neurons for the control and lesion groups (right). The distributions are the result of bootstrapping
- 1830 by randomly sampling neurons in 5,000 iterations. The distribution of differences between the
- 1831 obtained asymmetric scaling factors ( $\tau_{lesion} \tau_{control}$ ) was not significantly larger than zero (5<sup>th</sup>
- 1832 percentile = -0.1605).
- 1833 **d**. Distribution of asymmetric scaling factors ( $\tau_i$ ), computed from each individual neuron
- 1834 response function for the control and lesion groups. Each dot represents a single neuron (n = 45
- 1835 control group, n = 44 lesion group), and the neurons were sorted by asymmetric scaling factors
- 1836  $(\tau_i)$ . The means were not significantly different (right) (*t*-statistic = 0.3277, P = 0.627, *t*-test).
- e. Value predictions based on a TD learning model trained using the assumptions of Model 2 and
  the asymmetric scaling factors derived from the data. The model did not show any optimistic
  bias in the value predictors of the model trained with the lesion-derived asymmetric scaling
  factors.
- 1841 f. TD errors at cue show no signs of an optimistic bias in the model trained with the lesion-1842 derived asymmetric scaling factors.
- 1843 Centre of box plot shows the median; edges are 25th and 75th percentiles; and whiskers are the 1844 most extreme data points not considered as outliers.
- 1845
- 1846



1847

1848 Figure 6 | Model 1 can account for optimistic biases in reward-seeking behavior and cue1849 evoked dopamine responses.

1850 **a**. Schematic of the analysis. A biophysical model was used to predict dopamine concentrations,

- receptor occupancies, and value learning based on firing rates of dopamine neurons recorded inTian et al. (2015).
- 1853 **b**. Average firing rates of dopamine neurons across the population for the control and lesion
- 1854 groups (left, n= 45 control group, n= 44 lesion group). Baseline firing rates were significantly
- 1855 greater in the lesion compared to the control group (right) (U-statistic = -2.429, P = 0.0151,
- 1856 single-sided Mann-Whitney U-test).

- 1857 c. Dopamine concentrations predicted from the firing rates of dopamine neurons based on the
- 1858 biophysical model of dopamine. Predictions for 90% reward trials are shown.
- 1859 **d**. Receptor occupancies predicted by the same biophysical model. Predictions for rewarded
- 1860 (left) and reward omission (right) trials in 90% reward trials are shown separately for D1R (left)
- and D2R (right), respectively (n = 45 control group, n = 44 lesion group).
- 1862 e. Mean dopamine concentrations at baseline predicted by the model (U-statistic = -2.109, P =
- 1863 0.0175, single-sided Mann-Whitney U-test).
- 1864 **f**. Mean receptor occupancies at baseline predicted by the model (n = 45 control group, n = 44
- 1865 lesion group). There is a significant increase in occupancies for both the D1R and D2R in the
- 1866 lesion compared to the control group (U-statistic = -2.1664, P = 0.0151, U-statistic = -2.1328, P
- 1867 = 0.0165 for D1R and D2R respectively, single-sided Mann-Whitney U-test).
- 1868 g. Schematic showing the model predicted changes in dopamine concentrations and receptor
- 1869 occupancies for the control (black) and lesion (red) groups. The arrows depict the increase or
- 1870 decrease in occupancy for a positive or negative dopamine transient of a fixed magnitude.
- 1871 **h**. Changes in receptor occupancy as a function of dopamine transients predicted by the model.
- 1872 The slope for the positive and negative domains correspond to the receptor sensitivities of D1R
- 1873 and D2R ( $\alpha^+$ ,  $\alpha^-$ ), respectively.
- 1874 i. Asymmetric scaling factors derived from the receptors' sensitivities for the control and lesion
- 1875 groups (i.e.,  $\tau$  in model 1, n = 45 control group, n = 44 lesion group). There was a significant
- 1876 increase in the lesion group with respect to controls (U-statistic = -12.205,  $P < 1.0 \times 10^{-6}$ , single-
- 1877 sided Mann-Whitney U-test). Note that the increase in the asymmetry was driven mainly due to
- 1878 decreases in D2R sensitivity (panel h).
- **j**. Value predictions at baseline in a TD learning model trained with the receptor sensitivities
- 1880 derived from the biophysical. There was a significant increase in the value predictors at baseline
- 1881 in the model using the lesion group's derived parameters with respect to control. controls (*t*-
- 1882 statistic = -6.417, P <  $1.0 \times 10^{-6}$ , *t*-test).
- 1883 k. Value predictions at convergence of a TD learning model trained using the assumptions of
- 1884 Model 1 and the asymmetric scaling factors derived from receptors' sensitivities predicted by the
- 1885 biophysical model. The model led to a significant increase in the value predictions for all cues
- 1886 (U-statistic = -4.690,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.734,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 1.0 \ge 10^{-4}$ , U-statistic = -4.602,  $P < 10^{-4}$ ,  $P < 10^{-4$

1887 1.0 x 10<sup>-4</sup>, single-sided Mann-Whitney U-test, for the 10%, 50% and 90% reward probability

1888 cues) and an optimistic bias in the normalized value prediction to the 50% reward probability cue 1889 (*t*-statistic = -5.576,  $P < 1.0 \times 10^{-4}$ , *t*-test) in accordance with the anticipatory licking observed in 1890 the data.

- 1891 I. Predicted cue responses. There is an overall decrease in RPEs in lesioned animals (left) due to
- 1892 an increase in the baseline (pre-cue) value prediction (U-statistic =4.932,  $P < 1.0 \text{ x } 10^{-5}$ , U-
- 1893 statistic = -3.658, P = 0.00025, U-statistic = 4.734,  $P < 1.0 \times 10^{-4}$ , single-sided Mann-Whitney
- 1894 U-test for the 10%, 50% and 90% reward probability cues), which is consistent with the
- 1895 decreases in the absolute magnitudes of dopamine cue-evoked responses in the lesion group (Fig.
- 1896 4c). The normalized TD errors at for the 50% reward probability cue show signs of an optimistic
- 1897 bias (U-statistic = -4.624, P <  $1.0 \times 10^{-4}$ , single-sided Mann–Whitney U-test).
- 1898 Centre of box plot shows the median; edges are 25th and 75th percentiles; and whiskers are the
- 1899 most extreme data points not considered as outliers.







- a. Schematic of the events occurring at dopaminergic axon terminal. Pre- and post-synaptic sites
   predominantly express D2s (short) and D2l (long) subtypes, respectively.
- b. "Relative reversal learning (RRL)" under placebo conditions as a function of dopamine striatal
  synthesis capacity measured with PET radio imaging (black dots, left y-axis, bottom x-axis).

1909 Figure taken from Cools et al.  $(2009)^{24}$ . Positive values of RRL indicate a bias favoring learning

1910 from gains relative to losses, and vice versa for negative values of RRL. There was a positive

- 1911 relationship between RRL and dopamine synthesis capacity. Model 1 predictions of RRL ( $2\tau$  –
- 1912 1 in Model 1) as a function of baseline dopamine using the receptors occupancy curve,
- 1913 recapitulate the positive relationship shown in the results from Cools et al.  $(2009)^{24}$  (gray line,
- 1914 right y-axis, top x-axis).
- 1915 c. The change in RRL induced by bromocriptine was negatively correlated with striatal
- 1916 dopamine synthesis capacity. Figure from Cools et al. (2009)<sup>24</sup> (black dots, left y-axis, bottom x-
- 1917 axis). Model 1 recapitulates qualitatively the effect of bromocriptine in RRL, equivalent to
- 1918  $\Delta(2\tau 1)$ . The solid light green line represents the  $\Delta(2\tau 1)$  when considering bromocriptine's
- 1919 effect on *D2l occupancy only*; the dashed line represents the  $\Delta(2\tau 1)$  when both *D2l and D2s*
- 1920 occupancy was considered; and the dark green line represents the  $\Delta(2\tau 1)$  when both D2l and
- 1921 *D2s activation* was considered (this includes the fact that bromocriptine is a partial agonist for
- 1922 the D2l and D2s receptors). The curves were obtained by imposing a concentration of  $10^{0.8}$  nM
- 1923 of bromocriptine in the biophysical model.
- 1924 **d.** Receptor occupancy curves for the D2l receptors at baseline (grey line) and in the presence of
- 1925 10<sup>0.8</sup> nM of bromocriptine: Solid light green line corresponds to considering bromocriptine's
- 1926 effects on D2l receptors occupancy alone; dashed line, corresponds to considering
- 1927 bromocriptine's effects on both D2l and D2s receptors; solid dark green line corresponds to
- 1928 considering bromocriptine's effect on the activation curves of both D2l and D2s receptors. The
- 1929 binding of the drug to the D2l receptors alone causes an increase in occupancy. This happens to a
- 1930 larger extent when starting from a low dopamine level at baseline than in high dopamine levels.
- 1931 The binding of the drug to D2s receptors in addition to D2l receptors causes a rightward shift in
- 1932 the curves. The activation levels are lower than 1 even at the drug levels where occupancy is
- 1933 close to 1, due to the lower efficiency of bromocriptine in receptor activation (Methos 4.1). See
- 1934 Extended Figure 6 and 7 for the effect of changing bromocriptine's concentration and efficiency
- 1935 of activation.
- 1936 e. Same as in panel d. but now reporting  $(2\tau 1)$  calculated from the D2l receptor's occupancy
- 1937 and activation curves. An increase in  $2\tau 1$  happens to a larger extent when starting from a low
- 1938 dopamine level than from high dopamine level.

- 1939 **f.** Same as in panel **d.** but now reporting  $\Delta(2\tau 1)$  calculated from the D2l receptor's occupancy
- and activation curves. Model 1 recapitulates qualitatively the effect of bromocriptine on RRL.
- 1941 g. The effect of PD medication (L-DOPA) on loss aversion is negatively correlated with their
- 1942 off-medication depression score. Figure from Timmer et al.  $(2018)^{71}$ .
- 1943 h. Model 1 recapitulates qualitatively the effect of PD medication in loss aversion. We assumed
- 1944 that the asymmetry in favor of learning from losses relative to gains  $(1 \tau)_{off}$  scales with the
- 1945 baseline dopamine levels. Given this, we derived a distribution of off-medication baseline
- 1946 dopamine levels centered around the mean  $(1 \tau)_{off}$  derived from the data of Timmer et al.
- 1947 (2018)<sup>71</sup> (see methods 0). We then imposed a fixed increase in baseline dopamine to simulate L-
- 1948 DOPA effects. We derived the new loss-aversion parameter  $(1 \tau)_{on}$  at the shifted baseline
- 1949 dopamine levels. The y-axis shows the change in loss aversion for each sample of the
- 1950 distribution of baseline dopamine levels. If the off-medication depression score is correlated with
- 1951  $(1 \tau)_{off}$  then model would predict the result in Timmer et al.  $(2018)^{71}$ .
- 1952 PD: Parkinson's disease.

## 1954 Extended data Figures





1956 Extended Data Fig. 1 | Variables of model 1 show convergence irrespective of the value of
1957 the decay factor.

**a**. Value predictors *V* (left), *P* population (middle) and *N* population (right) across trials of

1959 training for an RL agent of model 1. Color of lines denotes the value of the decay factor ( $\beta$ ) in

1960 the update rules for the *P* and *N* populations. Colormap is the same for all figures (left). All the

1961 model variables show convergence for every value of the decay factor  $\beta$ .

- 1962 **b**. Difference in the variables estimates between consecutive trials of training, for the value
- 1963 predictors V (left,  $\Delta V$ ), P population (middle,  $\Delta P$ ) and N population (right,  $\Delta N$ ). All the variables
- 1964 show convergence for every value of the decay factor  $\beta$  (shown as a  $\Delta V$ ,  $\Delta P$ ,  $\Delta N$  equal to zero).



1966

#### Extended Data Fig. 2 | RL model fits to the trial-by-trial anticipatory licking responses. 1967

1968 a. TD learning fits reveal no significant difference across groups in the learning rate (left, U-

1969 statistic = -4.954, P =0620, two-sided Mann-Whitney U-test) nor in the linear mapping between

1970 value predictions and anticipatory licking responses (U-statistic = -1.445, P = 0.148, two-sided

1971 Mann-Whitney U-test).

1972 **b**. Model fits of TD learning with reward sensitivity reveal no difference across groups in the

1973 learning rate (left, U-statistic = 0.206, P = 0.836, two-sided Mann-Whitney U-test) nor in the

- 1974 linear mapping between value predictions and anticipatory licking responses (middle, U-statistic
- 1975 = -0.7844, P = 0.4327, two-sided Mann-Whitney U-test), nor in the reward sensitivity (right) (U-
- 1976 statistic 0.545, P = 0.605, two-sided Mann-Whitney U-test).
- 1977 **c**. Model fits of TD learning with asymmetric learning rates for positive vs negative RPEs. This
- 1978 model reveals a significant difference across groups in the asymmetry between  $\alpha^+$  and  $\alpha^-$  (U-
- 1979 statistic = -4.678,  $P < 1.0 \times 10^{-5}$ , two-sided Mann-Whitney U-test) and a small but significant
- 1980 difference between the linear mapping between value predictions and anticipatory licking
- 1981 responses (right, U-statistic = 2.33, P = 0.02, two-sided Mann-Whitney U-test).

1982





1985 Extended Data Fig. 3 | Signatures of distributional reinforcement learning model are
1986 preserved after habenula lesions.

1987 **a**. RPE -evoked responses at outcome as a function of the theoretical RPE for each trial type. The

1988 figure shows the average response function across neurons from the control group. The

- 1989 computation of zero-crossing points and asymmetric scaling factors is carried out in the 'utility
- 1990 space' (the average response function ) as in  $^{36}$  to account for response nonlinearities.
- 1991 **b**. Example of the response function of 3 dopamine neurons from the control group ordered by
- 1992 their asymmetric scaling factors: pessimistic, neutral and optimistic, from top to bottom.
- 1993 c. Computation of zero-crossing points for the neurons in B. The reversal points for each cell  $(Z_i)$
- 1994 were defined as the point in utility space that maximized the number of positive responses to
- 1995 points greater than  $Z_i$  plus the number of negative responses to points less than  $Z_i$ . The y-axis
- 1996 shows the sum of responses below and above each point in the utility space. The zero-crossing
- 1997 point is shown as the maxima in this function.
- 1998 **d**. Computation of asymmetric scaling factors for the neurons in c. Here, the responses functions
- in b have been projected to the utility space in A and realigned according to their zero-crossing
- 2000 points. The asymmetric learning rates ( $\alpha^+$ ,  $\alpha^-$ ) are taken to be the slopes of these response
- 2001 functions.
- 2002
- 2003



2005 Extended Data Fig. 4 | Distributional reinforcement learning variables from the Habenula
2006 lesion dataset.

2007 **a**. Distribution of asymmetric scaling factors for the dopamine neurons from the control (left)

and lesion (right) groups. The error bars were derived by randomly sampling trials to compute

2009 the asymmetric scaling factors for 1000 iterations.

- 2010 **b**. Distribution of zero crossing points for the control (left) and lesion(right) groups. The error
- 2011 bars were derived as in a.
- c. Correlation of asymmetric scaling factors (x-axis) and zero-crossing points (y-axis) computed
   on disjoint halves of trials for an example partition.
- 2014 **d**. Distribution of correlation coefficients between asymmetric scaling factors (x-axis) and zero-
- 2015 crossing points (y-axis) across disjoint halves of trials for 1000 partitions for the control and
- 2016 lesion groups.

2017 e. Correlation between zero-crossing points computed on disjoint halves of trials for an example2018 partition.

- 2019 f. Distribution of correlation coefficients between zero-crossing points computed on disjoint
- 2020 halves of trials for 1000 partitions for the control and lesion groups.
- 2021 g. Correlation between asymmetric scaling factors computed on disjoint halves of trials for an2022 example partition.
- 2023 h. Distribution of correlation coefficients between asymmetric scaling factors computed on
- 2024 disjoint halves of trials for 1000 partitions for the control and lesion groups.

2025





2027

Extended Data Fig. 5 | Biases in cue-evoked responses in the Habenula lesion data cannot
be explained by asymmetric scaling of RPEs (Model 2).

**a**. Value predictors derived from model 1 with TD learning for a set of baseline dopamine levels

2031 (colormap). The optimistic and pessimistic biases are present.

- 2032 **b**. Cue responses derived from model 1 with TD learning for a set of baseline dopamine levels
- 2033 (colormap). The optimistic and pessimistic biases are revealed when the responses are

2034 normalized.

- 2035 c. Value predictors derived from model 2 with TD learning for a set of baseline dopamine levels
- 2036 (colormap). The optimistic and pessimistic biases are present.
- 2037 **d**. Cue responses derived from model 2 with TD learning for a set of baseline dopamine levels
- 2038 (colormap). The optimistic and pessimistic biases are absent in both the normalized and the raw2039 TD errors.
- e. Mean across the distribution of value predictors derived from model 1 with distributional TD
- 2041 learning for a set of baseline dopamine levels (colormap). The optimistic and pessimistic biases2042 are present.
- 2043 f. Mean across the distribution of cue responses derived from model 1 with distributional TD
- 2044 learning for a set of baseline dopamine levels (colormap). The optimistic and pessimistic biases2045 are revealed when the responses are normalized.
- 2046 g. Mean across the distribution of value predictors derived from model 2 with distributional TD
- 2047 learning for a set of baseline dopamine levels (colormap). The optimistic and pessimistic biases2048 are present.
- h. Mean across the distribution of cue responses derived from model 2 with distributional TD
- 2050 learning for a set of baseline dopamine levels (colormap). The optimistic and pessimistic biases
- are absent in both the normalized and the raw TD errors.
- 2052
- 2053



2054

## Extended Data Fig. 6 | Model 1 predicts asymmetric learning rates and the effect of bromocriptine in healthy humans given inter-individual differences in baseline dopamine.

a. Occupancy curves for the D2l receptors at baseline (grey line) and when considering
bromocriptine's effects in D2l receptors alone. The binding of the drug to the D2l receptors alone
causes an increase in the occupancy. This happens to a larger extent when starting from a low
dopamine level at baseline than in high dopamine levels.

- **b**. Occupancy curves for the D2l receptors at baseline (grey line) and when considering
- bromocriptine's effects in both D2l and D2s receptors. The binding of the drug to D2s receptors
- 2063 causes a rightwards shifts in the curves.

2064 c. Activation curves for the D2l receptors at baseline (grey line) and when considering

- bromocriptine's effects in D2l receptors alone, including the *partial* quality of the agonism of this drug on the receptor (i.e., efficiency <1).</p>
- 2067 **d**. Activation curves for the D2l receptors at baseline (grey line) and when considering
- bromocriptine's effects in both D2l and D2s receptors, including the *partial* quality of the agonism.
- 2070 e. Relative reversal learning (RRL) calculated as  $2\tau 1$  in model 1, as a function of baseline
- 2071 dopamine (x-axis) and drug concentration (color) using the receptors occupancy curve,
- 2072 considering only bromocriptine's effect in D2l receptors.
- 2073 **f**. Relative reversal learning (RRL) calculated as  $2\tau 1$  in model 1, as a function of baseline
- 2074 dopamine (x-axis) and drug concentration (color) using the receptors occupancy curve,
- 2075 considering bromocriptine's effect in both D2l and D2s receptors.
- 2076 g.  $2\tau 1$  in model 1, as a function of baseline dopamine (x-axis) and drug concentration (color) 2077 using the receptors activation curve, considering only bromocriptine's effect in D2l receptors.
- 2078 **h**.  $2\tau 1$  in model 1, as a function of baseline dopamine (x-axis) and drug concentration (color) 2079 using the receptors activation curve, considering bromocriptine's effect in both D21 and D2s 2080 receptors.
- 2081 i. The change in  $2\tau 1$  induced by the drug at different concentrations (color) with respect to
- 2082 the baseline condition, as a function of baseline dopamine (x-axis). The curves represent the 2083 change when calculating  $2\tau - 1$  from the occupancy curves considering only D2l binding.
- 2084 **j**. The change in  $2\tau 1$  induced by the drug at different concentrations (color) with respect to
- 2085 the baseline condition, as a function of baseline dopamine (x-axis). The curves represent the
- 2086 change when calculating  $2\tau 1$  from the occupancy curves considering both D2l and D2s
- 2087 binding
- 2088 **k**. The change in  $2\tau 1$  induced by the drug at different concentrations (color) with respect to
- 2089 the baseline condition, as a function of baseline dopamine (x-axis). The curves represent the
- 2090 change when calculating  $2\tau 1$  from the activation curves considering only D2l activation.
- 2091 I. The change in  $2\tau 1$  induced by the drug at different concentrations (color) with respect to
- 2092 the baseline condition, as a function of baseline dopamine (x-axis). The curves represent the

- 2093 change when calculating  $2\tau 1$  from the activation curves considering both D2l and D2s
- activation.
- 2095 The parameters of efficiency of activation of D2 receptors by the drug  $(D2l_{eff}, D2s_{eff})$  used in
- 2096 each column are reported at the bottom of the figure.

2097



2100 Extended Data Fig. 7 | Robustness of the effect of bromocriptine in the relative reversal

2101 learning calculated from the occupancy curves to the choice of the drug efficiency

2102 parameter.

- 2103 The qualitative effects on bromocriptine in the change in relative reversal learning  $\Delta(2\tau 1)$
- 2104 calculated from the D2 *occupancy* curves. Results hold regardless of the choice of the efficiency
- 2105 of the drug on D2l (rows) or D2s (columns) efficiency.

2106



2109 Extended Data Fig. 8 | Robustness of the effect of bromocriptine in the relative reversal

- 2110 learning calculated from the activation curves to the choice of the drug efficiency
- 2111 parameter.

- 2112 The qualitative effects on bromocriptine in the change in relative reversal learning  $\Delta(2\tau 1)$
- 2113 calculated from the D2 activation curves. Results hold regardless of the choice of the efficiency
- 2114 of the drug on D2l (rows) or D2s (columns) efficiency.





# Extended Data Fig. 9 | The qualitative aspects of Model 1 are preserved irrespective of the assumption made about the changes in baseline dopamine caused by dopamine transients.

2120 **a**. Computation of receptor sensitivities (i.e., slope of dose-occupancy curves,  $\alpha^+$ ,  $\alpha^-$ ) assuming

2121 logarithmic (left) or linear (middle) changes in baseline dopamine induced by dopamine

2122 transients (log $\Delta$ DA, lin $\Delta$ DA, respectively). The absolute magnitude of the slopes differs

2123 depending on the assumption made about the changes in baseline dopamine (logarithmic vs

2124 linear) but the asymmetric scaling factor presents only a small shift in the curve as a function of

2125 baseline dopamine (right). The qualitative aspects of the model (i.e., non-monotonic relationship

2126 of the asymmetric scaling factor with baseline dopamine) is preserved regardless on this

assumption.



2129



**a**. Distributions of the slopes of the change in firing rate derived as a function of RPEs in the

2133 positive and negative domains, computed in the linear (left) or logarithmic (right) scale,

2134 calculated at a single neuron level. The slopes are asymmetric if considered in the linear scale,

2135 with the negative transients presenting a shallower slope than the positive ones. The slopes are

2136 symmetric if considered in the logarithmic scale.

- **b.** Distributions of the slopes of the change in dopamine levels derived from the biophysical
- 2138 model as a function of RPEs in the positive and negative domains, computed in the linear (left)
- 2139 or logarithmic (right) scale, calculated at a single neuron level. The slopes are again asymmetric
- 2140 if considered in the linear scale but symmetric if considered in the logarithmic scale.
- c. Slope of the change in receptor occupancy derived from the biophysical model for a given
- 2142 RPE in the positive and negative domains, computed in the linear (left) or logarithmic (right)
- scale, calculated at a single neuron level. The slopes are symmetric if considered in the linear
- 2144 scale but asymmetric if considered in the logarithmic scale.





Extended Data Fig. 11 | Relationship between changes in firing rates and changes in
dopamine concentration derived from the biophysical model.

- **a**. Linear fits to the relationship between changes in firing rates and changes in dopamine
- 2150 concentration evoked by the TD error at outcome in the linear scale for the control group. The
- 2151 fits are done separately for each trial type.

- **b.** Same as a, but fits are done in the logarithmic scale.
- 2153 c. Same as a, but fits are done for the lesion group.
- **d**. Same as c, but fits are done in the logarithmic scale.
- 2155 e. Distribution of the Pearson correlation coefficients (top) and means squared error (MSE,
- bottom) between the predicted change in dopamine concentration by the linear regression and the
- 2157 ground truth derived from the biophysical model. The coefficients are derived from the fits in
- figures a-e, done by pooling all trials for each trial type (each point each trial type, with black for
- 2159 control and red for lesion group). There was a significant increase in the Pearson correlation
- 2160 coefficient and a near significant decrease in the MSE if the changes are considered to happen in
- the logarithmic scale.
- 2162 **f**. Same as E, but the linear regression fits are done for each neuron separately by pooling all
- trials. There was a significant increase in the single-cell distribution of Pearson correlation
- 2164 coefficients (top) and a significant decrease in the MSE distribution (bottom) if the changes are
- 2165 considered to happen in the logarithmic scale.
- 2166
- 2167





2169 Extended Data Fig. 12 | Model 1 captures signatures of the data irrespective of the choice of

### 2170 the decay factor and is compatible with distributional RL.

a. Model 1 with standard TD learning. Simulations were run using the receptors sensitivities

2172 from the biophysical models and data-derived asymmetric scaling factors (see Methods 3.3).

2173 The model's predictions capture the signatures in cue-evoked dopamine responses (left) and

- 2174 value predictions (right) irrespective of the choice of the decay factor ( $\beta$ ).
- **b**. Model 1 within the distributional RL framework (see Methods 3.3). The model's predictions
- also capture the signatures in cue-evoked dopamine responses (left) and value predictions (right)
- 2177 irrespective of the choice of the decay factor ( $\beta$ ). Bottom row shows the distribution of value
- 2178 predictors for each reward-predictive cue.



Extended Data Fig. 13 | Distributional reinforcement learning with D1 and D2 populations
(Model 1).

2180

a. Schematic of the distributional RL model with D1 and D2 populations. The schematic represents three different value predictors (pessimistic, neutral and optimistic from left to right) with their respective *P* and *N* neurons. The level of optimism of each individual value predictor is determined by the scaling factors of the individual dopamine RPE-evoked responses ( $\alpha_i^+, \alpha_i^-$ , represented by the color in the colormap from purple to pink) and allows the model to encode information about the distribution of rewards (bottom). The global level of 'optimism' or

- 2189 'pessimism' of the agent is given by the re-scaling of the RPEs by the P and N receptors
- 2190 sensitivities in the model ( $\phi^+$ ,  $\phi^-$ , represented with the color saturation).
- b. Example of a Bernoulli distribution, equivalent to the reward distribution predicted by the
  50% cue.
- 2193 c. Distribution of expectiles learnt by the distributional RL model with D1 and D2 population for
- the reward distribution in b. The expectiles are sorted based on the asymmetric scaling factor of
- each individual dopamine neuron. Colormap represents the level of optimistic or pessimism ofeach agent.
- **d**. Samples from the decoded distributions for the set of expectiles in c. The probability density is
- 2198 bimodal, in accordance with the distribution in b. As the agents goes from pessimism to
- 2199 optimism, the probability density modes change in their relative magnitude.